US20090181159A1 - Methods for applying an application material to an implantable device - Google Patents
Methods for applying an application material to an implantable device Download PDFInfo
- Publication number
- US20090181159A1 US20090181159A1 US12/331,290 US33129008A US2009181159A1 US 20090181159 A1 US20090181159 A1 US 20090181159A1 US 33129008 A US33129008 A US 33129008A US 2009181159 A1 US2009181159 A1 US 2009181159A1
- Authority
- US
- United States
- Prior art keywords
- ultrasonic
- implantable device
- delivery apparatus
- material delivery
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 title claims abstract description 360
- 238000000034 method Methods 0.000 title claims abstract description 89
- 239000011248 coating agent Substances 0.000 claims abstract description 23
- 238000000576 coating method Methods 0.000 claims abstract description 23
- 238000000889 atomisation Methods 0.000 claims description 14
- 239000003146 anticoagulant agent Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 5
- 230000001028 anti-proliverative effect Effects 0.000 claims description 5
- 229940127219 anticoagulant drug Drugs 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 230000003266 anti-allergic effect Effects 0.000 claims description 4
- 230000002927 anti-mitotic effect Effects 0.000 claims description 4
- 230000000702 anti-platelet effect Effects 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 239000012867 bioactive agent Substances 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 229950003499 fibrin Drugs 0.000 claims description 4
- 229920002988 biodegradable polymer Polymers 0.000 claims description 3
- 239000004621 biodegradable polymer Substances 0.000 claims description 3
- -1 antidiabetics Substances 0.000 description 19
- 239000013543 active substance Substances 0.000 description 14
- 238000010586 diagram Methods 0.000 description 10
- 239000011148 porous material Substances 0.000 description 9
- 230000033001 locomotion Effects 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000005684 electric field Effects 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 238000004891 communication Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000560 biocompatible material Substances 0.000 description 4
- 239000004020 conductor Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 150000000921 Gadolinium Chemical class 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000000622 polydioxanone Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- NJNWCIAPVGRBHO-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical class OCC[N+](C)(C)C#P=O NJNWCIAPVGRBHO-UHFFFAOYSA-N 0.000 description 1
- ZHYGVVKSAGDVDY-QQQXYHJWSA-N 7-o-demethyl cypher Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](O)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 ZHYGVVKSAGDVDY-QQQXYHJWSA-N 0.000 description 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 230000005355 Hall effect Effects 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000221931 Hypomyces rosellus Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000000228 antimanic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 150000001553 barium compounds Chemical class 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 1
- 229960004648 betamethasone acetate Drugs 0.000 description 1
- 150000001622 bismuth compounds Chemical class 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- AINBZKYUNWUTRE-UHFFFAOYSA-N ethanol;propan-2-ol Chemical compound CCO.CC(C)O AINBZKYUNWUTRE-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- XVDBWWRIXBMVJV-UHFFFAOYSA-N n-[bis(dimethylamino)phosphanyl]-n-methylmethanamine Chemical compound CN(C)P(N(C)C)N(C)C XVDBWWRIXBMVJV-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
- 229920005670 poly(ethylene-vinyl chloride) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920005569 poly(vinylidene fluoride-co-hexafluoropropylene) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001692 polycarbonate urethane Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 229960001302 ridaforolimus Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
- 229950009819 zotarolimus Drugs 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/02—Processes for applying liquids or other fluent materials performed by spraying
- B05D1/04—Processes for applying liquids or other fluent materials performed by spraying involving the use of an electrostatic field
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B13/00—Machines or plants for applying liquids or other fluent materials to surfaces of objects or other work by spraying, not covered by groups B05B1/00 - B05B11/00
- B05B13/02—Means for supporting work; Arrangement or mounting of spray heads; Adaptation or arrangement of means for feeding work
- B05B13/0221—Means for supporting work; Arrangement or mounting of spray heads; Adaptation or arrangement of means for feeding work characterised by the means for moving or conveying the objects or other work, e.g. conveyor belts
- B05B13/0228—Means for supporting work; Arrangement or mounting of spray heads; Adaptation or arrangement of means for feeding work characterised by the means for moving or conveying the objects or other work, e.g. conveyor belts the movement of the objects being rotative
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B17/00—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups
- B05B17/04—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups operating with special methods
- B05B17/06—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups operating with special methods using ultrasonic or other kinds of vibrations
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B5/00—Electrostatic spraying apparatus; Spraying apparatus with means for charging the spray electrically; Apparatus for spraying liquids or other fluent materials by other electric means
- B05B5/08—Plant for applying liquids or other fluent materials to objects
- B05B5/087—Arrangements of electrodes, e.g. of charging, shielding, collecting electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
Definitions
- the present invention relates generally to medical devices, and more particularly to methods for applying an application material to an implantable device.
- Percutaneous transluminal coronary angioplasty is a procedure for treating heart disease. This procedure generally entails introducing a catheter assembly into the cardiovascular system of a patient via the brachial or femoral artery and advancing the catheter assembly through the coronary vasculature until a balloon portion thereon is positioned across an occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress against the atherosclerotic plaque of the lesion to remodel the vessel wall. Subsequently, the balloon is deflated to allow the catheter assembly to be withdrawn from the vasculature.
- PTCA Percutaneous transluminal coronary angioplasty
- PTCA While PTCA is widely used, it suffers generally from two unique problems.
- the blood vessel may suffer acute occlusion immediately after or within the initial hours after the dilation procedure. Such occlusion is referred to as “abrupt closure.”
- Abrupt closure occurs in approximately five percent of cases in which PTCA is employed.
- the primary mechanisms of abrupt closures are believed to be elastic recoil, vasospasm, arterial dissection, and/or thrombosis.
- the second problem associated with this procedure is the re-narrowing of an artery after an initially successful angioplasty. This re-narrowing is referred to as “restenosis,” which typically occurs within the first six months after angioplasty. Restenosis is believed to be due to, among other things, the proliferation and migration of cellular components from the arterial wall, as well as through geometric changes in the arterial wall referred to as “remodeling.”
- an expandable interventional device or prosthesis may be implanted in the lumen to maintain the vascular patency. Additionally, to better effectuate the treatment of such vascular disease, it may be preferable to load an intraluminal device or prosthesis with one or more beneficial agents, such as antiproliferatives, for delivery to a lumen.
- beneficial agents such as antiproliferatives
- One commonly applied technique for the local delivery of a drug is through the use of a polymeric carrier coated onto the surface of a stent, as disclosed in Berg et al., U.S. Pat. No. 5,464,650, the disclosure of which is incorporated herein by reference thereto. Such conventional methods and products generally have been considered satisfactory for their intended purpose.
- implantable devices such as stents may be difficult to coat without webbing, cobwebs, or other defects due to their generally intricate geometry. They may also be difficult to uniformly coat (i.e. on the ablumenal, luminal, and sidewall surfaces). Because of these challenges, many commercialized drug eluting stents are being coated by a spray process. However, spray coating may suffer generally from the following: reduced coating speed, reproducibility, and/or coating efficiency (i.e. the amount of material sprayed actually coating the device).
- a method for applying a coating to an implantable device includes positioning an implantable device relative to an ultrasonic material delivery apparatus.
- the ultrasonic material delivery apparatus includes an ultrasonic generator. At least one of the ultrasonic material delivery apparatus and the implantable device has a positive or negative electric charge.
- the method includes applying an application material to the implantable device using the ultrasonic material delivery apparatus.
- a method for applying a coating to an implantable device includes positioning an implantable device between a conductive member and an ultrasonic material delivery apparatus.
- the ultrasonic material delivery apparatus includes an ultrasonic generator.
- the conductive member has either a positive or a negative charge.
- the method includes applying an application material to the implantable device using the ultrasonic material delivery apparatus.
- a method for applying a coating to an implantable device includes positioning a stent between an ultrasonic material delivery apparatus and a grounded conductive member.
- the ultrasonic material delivery apparatus includes an ultrasonic generator. At least one of the ultrasonic material delivery apparatus and the stent has a positive or negative electric charge.
- the method includes applying ultrasonic energy to an application material using the ultrasonic generator.
- the method also includes applying the application material to the stent using the ultrasonic material delivery apparatus.
- a method for applying a coating to an implantable device includes positioning a conductive member between a stent and an ultrasonic material delivery apparatus.
- the ultrasonic material delivery apparatus includes an ultrasonic generator.
- the conductive member has a positive or a negative charge.
- the method includes applying ultrasonic energy to an application material using the ultrasonic generator.
- the method also includes applying the application material to the stent using the ultrasonic material delivery apparatus.
- the ultrasonic material delivery device includes a material delivery device. At least one of the material delivery device and the implantable device has a positive or negative electric charge.
- the material delivery device in further embodiments, is selectively electrically isolated from the ultrasonic generator.
- the material delivery apparatus in still further embodiments, combines ultrasonic atomization with a flowing gas stream.
- the ultrasonic material delivery apparatus in some embodiments, has a positive or negative electric charge and the positive or negative electric charge is of sufficient strength to facilitate atomization of the application material.
- the implantable device in some embodiments, is positioned between the ultrasonic material delivery apparatus and a conductive member.
- the conductive member in further embodiments, has a positive or a negative charge or is grounded.
- the conductive member in some embodiments, is positioned between the implantable device and the ultrasonic material delivery apparatus.
- the conductive member in further embodiments, has a positive or a negative charge.
- the conductive member is an annular shaped ring.
- the implantable device, the ultrasonic material delivery apparatus, or the conductive member has a difference in electrical potential of less than or equal to about 100 kV in either a positive or negative polarity. Both the implantable device and the ultrasonic material delivery apparatus, in further embodiments, have either a positive or a negative charge.
- Applying the application material to the implantable device using the ultrasonic material delivery apparatus includes applying ultrasonic energy to the application material using the ultrasonic generator.
- the applied ultrasonic energy is sufficient to facilitate atomization of the application material.
- the application material includes a radiopaque material, at least one bioactive agent that is an anti-proliferative, anti-inflammatory, antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic, antibiotic, antiallergic or antioxidant drug, a durable and/or biodegradable polymer, and/or a solvent.
- the implantable device in further embodiments, is a closure element and/or a stent.
- FIG. 1 illustrates a block diagram of an embodiment of a system for applying an application material to an implantable device, in accordance with the present invention.
- FIG. 2 illustrates an embodiment of a method for applying an application material to an implantable device, in accordance with the present invention.
- FIG. 3 illustrates a block diagram of another embodiment of a system for applying an application material to an implantable device, in accordance with the present invention.
- FIG. 4 illustrates another embodiment of a method for applying an application material to an implantable device, in accordance with the present invention.
- FIG. 5 illustrates a block diagram of a further embodiment of a system for applying an application material to an implantable device, in accordance with the present invention.
- FIG. 6 illustrates a further embodiment of a method for applying an application material to an implantable device, in accordance with the present invention.
- FIG. 7 illustrates a block diagram of a still further embodiment of a system for applying an application material to an implantable device, in accordance with the present invention.
- FIG. 8 illustrates a still further embodiment of a method for applying an application material to an implantable device, in accordance with the present invention.
- FIG. 9 illustrates a block diagram of an even further embodiment of a system for applying an application material to an implantable device, in accordance with the present invention.
- FIG. 10 illustrates a schematic representation of an embodiment of a system for applying an application material to an implantable device, in accordance with the present invention.
- a coating nozzle for an implantable device such as a stent
- the coating solution may be atomized by a combination of ultrasonic energy and application of an electric field.
- the ultrasonic energy is present to atomize the solution while the electrical field is applied to the nozzle primarily to impart an electric charge to the droplets so that they are attracted to a grounded part to be coated.
- the applied electric field is high enough, it may also facilitate in the atomization.
- an electrical field to an ultrasonic material delivery apparatus, an implantable device, and/or a conductive member.
- the implantable device may be placed between the ultrasonic delivery apparatus and the conductive member.
- the conductive member may be placed between the ultrasonic delivery apparatus and the implantable device.
- the conductive member may be a single electrode, several electrodes that are interconnected, and/or a shaped electrode, such as a tubular, cylindrical, spherical, rectangular, and/or otherwise shaped electrode.
- Further embodiments include grounding no more than two of the ultrasonic material delivery apparatus, the implantable device, and/or the conductive member. Still further embodiments include grounding either the ultrasonic material delivery apparatus or the implantable device. By setting up an electric field between the ultrasonic material delivery apparatus and the implantable device, the application material may generally follow a curved trajectory towards the implantable device, thereby generally increasing the coating efficiency.
- Increased coating efficiency may be achieved by setting up an electric field between the ultrasonic material delivery apparatus and the conductive member and positioning the implantable device between the ultrasonic delivery apparatus and the conductive member. Due to the position of the conductive member, the application material may generally follow a curved trajectory towards the implantable device, thereby generally increasing the coating efficiency. In another embodiment, a focusing of application material droplets towards the implantable device may be achieved rather than attracting the droplets to the implantable device. Focusing the application material droplets may be achieved by positioning the conductive member between the ultrasonic delivery apparatus and the implantable device, and applying an electrical potential of the same sign to both the conductive member and the ultrasonic delivery apparatus. Use of a properly designed and positioned conductive member may repel application material droplets that are not on a trajectory toward the implantable device, and redirect them on a trajectory towards the implantable device.
- FIG. 1 illustrates a block diagram of an embodiment of a system 100 for applying an application material 170 to an implantable device 180 , in accordance with the present invention.
- the system 100 includes an ultrasonic material delivery apparatus 110 that may apply an application material 170 to an implantable device 180 .
- the application material 170 may include beneficial agents, imaging materials, solvents, and/or other application materials.
- Beneficial agents may include analgesics, antipyretics, antiasthmatics, antibiotics, antidepressants, antidiabetics, antifungal agents, antihypertensive agents, anti-inflammatories including non-steroidal and steroidal, antineoplastics, antianxiety agents, immunosuppressive agents, antimigraine agents, sedatives, hypnotics, antianginal agents, antipsychotic agents, antimanic agents, antiarrhythmics, antiarthritic agents, antigout agents, anticoagulants, thrombolytic agents, antifibrinolytic agents, hemorheologic agents, antiplatelet agents, anticonvulsants, antiparkinson agents, antihistamines, anti-restenosis agents, antipruritics, agents useful for calcium regulation, antibacterial agents, antiviral agents, antimicrobials, anti-infectives, bronchodilators, steroidal compounds and hormones, or combinations thereof.
- the active agent includes at least one of rapamycin, rapamycin analog, sirolimus, everolimus, zotarolimus, 40-epi-(Nl-tetrazolyl)-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, Biolimus A9 (Biosensors International, Singapore), deforolimus, AP23572 (Ariad Pharmaceuticals), temsirolimus, novolimus, myolimus, dexamethasone, dexamethasone acetate, dexmethasone phosphate, momentasone, cortisone, cortisone acetate, hydrocortisone, prednisone, prednisone acetate, betamethasone, betamethasone acetate, estradiol, acetaminophen, ibuprofen, naproxen, sulidac, heparin, taxol, paclitaxel, and/or combinations
- Imaging materials may include materials, such as radiopaque materials.
- radiopaque materials may include high-density materials such as gold, platinum, platinum/iridium, tantalum, tungsten, gadolinium salts, gadolinium complexes, bismuth compounds, barium compounds, and/or other radiopaque materials.
- the term radiopaque may include partial radiopacity as well as total radiopacity.
- Solvents may include methanol, ethanol isopropanol, n-propanol, isobutanol, sec-butanol, n-butanol, benzyl alcohol, alcohols, diethyl ether, tetrahydrofuran, 1,4-dioxane, ethers, butyl acetate, isopropyl acetate, ethyl acetate, methyl acetate, esters, acetone, 4-butanone, cyclopentanone, cyclohexanone, ketones, 1-methoxy-2-propanol, diacetone alcohol, methylene chloride, chloroform, carbon tetrachloride, 1,1,1-trichloroethane, trichloroethylene, chlorobenzene, freons, pentane, hexane, cyclohexane, n-heptane, n-octane, benzene,
- Other application materials may include polymeric materials comprised of phosphorylcholines, phosphorylcholine linked macromolecules, polyolefins, poly(meth)acrylates, polyurethanes, polyesters, polyanhydrides, polyphosphazenes, polyacrylates, acrylic polymers, poly(lactide-co-glycolides) (PLGA), polylactic acids (PLA), poly(hydroxybutyrates), poly(hydroxybutyrate-co-valerates), polydioxanones (PDO), polyorthoesters, polyglycolic acids (PGA), polycaprolactones (PCL), poly(glycolic acid-co-trimethylene carbonates), polyphosphoesters, polyphosphoester urethanes, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), polyalkylene oxalates, polyiminocarbonates, aliphatic polycarbonates, fibrins, fibrinogens, celluloses, star
- Implantable devices 180 may include endoprostheses, drug delivery stents, drug delivery catheters, stent-grafts, grafts, drug delivery balloons, guidewires, orthopedic implants, PFO closure devices, pacemaker leads, dental implants, fixation screws, indwelling catheters, ocular implants, pharmacotherapeutic implants, blood-contacting components of extracorporeal devices, staples, filters, needles, tubes, coils, wires, clips, screws, sensors, plates, conduits, portions thereof, closure elements for engaging tissue, combinations thereof, and/or other implantable devices.
- the implantable device may include an endoprosthesis for controlling the release of an active agent therefrom.
- an endoprosthesis can include the following: a supporting metal structure configured and dimensioned to be used within a body of a human; a porous body disposed on and at least partially covering the supporting metal structure, said porous body including a first biocompatible material having a plurality of pores; a therapeutically effective amount of an active agent disposed within said pores, said therapeutically effective amount of the active agent being capable of treating and/or preventing a disease; an elution rate controlling matrix disposed within the porous body so as to contain said active agent within said pores, said matrix material including a polymeric biocompatible material that at least partially controls an elution rate of the active agent from the pores; and said pores each having a dimension that is configured to at least partially determine said elution rate.
- the implantable device may include a stent for controlling the release of an active agent therefrom.
- a stent can include the following: a superelastic metal structure configured and dimensioned as a stent to be used within a lumen of an animal; a porous body disposed on and at least partially covering the superelastic metal structure, said porous body including a first biocompatible material having a plurality of pores; a therapeutically effective amount of an active agent disposed within at least a portion of the pores, said therapeutically effective amount of the active agent being capable of treating and/or preventing a disease; and an elution rate controlling matrix disposed on at least one surface of the porous body so as to contain the active agent within said at least a portion of the pores, said matrix material including a second biocompatible material that controls an elution rate of the active agent from the pores.
- the porous body is integrated with the supporting structure.
- the implantable device may include an endoprosthesis for controlling the release of an active agent therefrom.
- an endoprosthesis may include a supporting metal structure configured and dimensioned to be used within a body of a human, a coating body disposed on and at least partially covering the supporting metal structure, the coating body including a first biocompatible polymeric material having a largely homogeneous structure, a therapeutically effective amount of an active agent combined with the biocompatible polymeric material to make a largely homogeneous composition, the therapeutically effective amount of the active agent being capable of treating and/or preventing a disease, and the biocompatible polymeric material being either a durable or a biodegradable polymer.
- the ultrasonic material delivery apparatus 110 and/or the implantable device 180 may have a positive or negative electric charge when applying the application material 170 .
- Having an electric charge may include having an electric charge (i.e. positive, negative, or zero) with respect to a reference point.
- a reference point may include, for example, a ground.
- the electric charge may be directly applied to a component by applying a voltage potential to the component while applying the application material 170 .
- a component may be grounded before and/or during the application of the application material 170 . Grounding a component may include, for example, putting the component in electrical communication with a ground.
- the application material 170 may have the same electric charge as the ultrasonic material delivery apparatus 110 .
- the application material may also have a positive electric charge.
- the application material 170 may be generally attracted to or generally repelled from the implantable device 180 .
- the voltage potential between the application material 170 and the implantable device 180 may be sufficiently large to facilitate atomization of the application material 170 .
- the ultrasonic material delivery apparatus 110 may have a positive electric charge and the implantable device 180 may have a negative electric charge.
- the application material 170 may have a positive charge.
- the positively charged application material 170 in this example, may be generally attracted to the negatively charged implantable device 180 .
- the application material 170 may be generally more attracted to the implantable device 180 than in embodiments where only the ultrasonic material delivery apparatus 110 or the implantable device 180 have an electric charge. In embodiments where the electric charge of the implantable device 180 is generally opposite the electric charge of the ultrasonic material delivery apparatus 110 and where the opposite electric charges are relatively large, the application material 170 may be generally more attracted to the implantable device 180 than where the opposite electric charges are relatively small.
- the ultrasonic material delivery apparatus 110 may have the same or similar electric charge as the implantable device 180 (i.e. both generally positive or both generally negative).
- the application material 170 may have the same or similar electric charge as the implantable device 180 .
- the application material 170 in this example, may be generally repelled from the same or similarly charged implantable device 180 .
- the electric charge of the implantable device 180 is generally similar to the electric charge of the ultrasonic material delivery apparatus 110 and where the similar electric charges are relatively large, the application material 170 may be generally more repelled by the implantable device 180 than where the similar electric charges are relatively small.
- Repelling the application material 170 may be useful when it is desired to only apply the application material 170 to a surface closest to the ultrasonic material delivery apparatus 110 (i.e. the abluminal surface of a stent).
- the application material 170 may have a velocity that is sufficient to overcome any repulsing force from the opposing electric charges and apply the application material 170 to a surface closest to the ultrasonic material delivery apparatus 110 , but the velocity may be insufficient to overcome the repulsing force from the opposing electric charges to apply the application material 170 to another surface (i.e. the luminal surface of a stent).
- the ultrasonic material delivery apparatus 110 or the implantable device 180 may have an electric charge while the other device may be grounded. For example, if the ultrasonic material delivery apparatus 110 has an electric charge and the implantable device 180 is grounded, when the ultrasonic material delivery apparatus 110 applies the application material 170 to the implantable device 180 , the application material 170 may be more attracted to the grounded implantable device 180 than to an implantable device that is not grounded.
- the ultrasonic material delivery apparatus 110 when the ultrasonic material delivery apparatus 110 applies the application material 170 to the implantable device 180 , the application material 170 (which may not have an electric charge because the ultrasonic material delivery apparatus 110 is grounded) may be more attracted to the charged implantable device 180 than to an implantable device that is not electrically charged.
- FIG. 2 illustrates an embodiment of a method 200 for applying an application material to an implantable device, in accordance with the present invention.
- the method 200 may be used in conjunction with components of the system 100 described in connection with FIG. 1 and/or any other system for applying an application material to an implantable device described herein.
- the ultrasonic material delivery apparatus 110 and/or the implantable device 180 may have a positive or negative electric charge.
- An implantable device may be positioned relative to an ultrasonic material delivery apparatus, as represented by block 202 .
- Positioning an implantable device relative to an ultrasonic material delivery apparatus may include positioning the implantable device in a desired location and/or in a desired orientation.
- a stent may be positioned about 30 mm from a nozzle of an ultrasonic material delivery apparatus and/or oriented perpendicular to the application material being applied.
- an electric charge may be applied to the ultrasonic material delivery apparatus and/or the implantable device.
- the system component may be charged before applying the application material, but not during the application of the application material. In this example, the system component may nevertheless be charged by virtue of, for example, retaining the charge.
- the ultrasonic material delivery apparatus and/or the implantable device may be grounded.
- Applying the application material to the implantable device may include moving the implantable device and/or the ultrasonic material delivery apparatus with respect to each other.
- the ultrasonic material delivery apparatus may move along a length and/or width of the implantable device and the implantable device may rotate to facilitate a generally uniform application of the application material.
- FIG. 3 illustrates a block diagram of another embodiment of a system 300 for applying an application material 370 to an implantable device 180 , in accordance with the present invention.
- the system 300 of this other embodiment may be functionally similar to that of the system 100 previously described above and shown in FIG. 1 in most respects, wherein certain features will not be described in relation to this other embodiment wherein those components may function in the manner as described above and are hereby incorporated into this alternative embodiment described below.
- the system 300 includes an ultrasonic material delivery apparatus 310 that may apply an application material 370 to an implantable device 180 .
- the ultrasonic material delivery apparatus 310 may include an ultrasonic generator 320 .
- the ultrasonic generator 320 may include an ultrasonic power generator (not shown) and at least one transducer (not shown, but see description of FIG. 7 ).
- the ultrasonic generator 320 may generate ultrasonic energy to facilitate atomization of the application material 370 .
- the ultrasonic generator 320 may generate a transverse standing wave along the length, or at the end of, the nozzle.
- the ultrasonic material delivery apparatus 310 may include a material delivery apparatus 330 .
- the material delivery apparatus 330 may include, for example, a nozzle body and/or nozzle stem (see, for example, FIG. 7 ).
- the ultrasonic material delivery apparatus 310 and/or the implantable device 180 may have a positive or negative electric charge.
- the ultrasonic material delivery apparatus 310 or the implantable device 180 may be grounded.
- the material delivery apparatus 330 may be grounded before and/or during application of the application material. In other embodiments, the material delivery apparatus 330 may have an electric charge before and/or during application of the application material.
- the material delivery apparatus 330 in the present embodiment, may be selectively electrically isolated from the ultrasonic generator 320 .
- the ultrasonic generator 320 and/or the material delivery apparatus 330 may be electrically insulated.
- the implantable device 180 may be grounded, as shown in FIG. 3 .
- the optional ground lines connected to the material delivery apparatus 330 and the implantable device 180 indicate that both may be optionally grounded, only the implantable device 180 or the ultrasonic material delivery apparatus 310 (including the material delivery apparatus 330 ) may be grounded, in the present embodiment, before and/or during application of the application material 370 .
- FIG. 4 illustrates another embodiment of a method 400 for applying an application material to an implantable device, in accordance with the present invention.
- the method 400 may be used in conjunction with components of the systems 100 , 300 described in connection with FIGS. 1 and 3 and/or any other system for applying an application material to an implantable device described herein.
- the method 400 may utilize one of the material delivery apparatus 330 and the implantable device 180 .
- the method 400 of this other embodiment may be functionally similar to that of the method 200 previously described above and shown in FIG. 2 in most respects, wherein certain features will not be described in relation to this other embodiment wherein those method components may be performed in the manner as described above and are hereby incorporated into this alternative embodiment described below.
- An implantable device may be positioned relative to an ultrasonic material delivery apparatus, as represented by block 402 .
- Ultrasonic energy may be applied to an application material using an ultrasonic generator, as represented by block 404 .
- the ultrasonic generator used may include the ultrasonic generator 320 described above.
- the application material may be applied to the implantable device, as represented by block 406 .
- FIG. 5 illustrates a block diagram of a further embodiment of a system 500 for applying an application material 570 to an implantable device 180 , in accordance with the present invention.
- the system 500 of this other embodiment may be functionally similar to that of the systems 100 , 300 previously described above and shown in FIGS. 1 and 3 in most respects, wherein certain features will not be described in relation to this further embodiment wherein those components may function in the manner as described above and are hereby incorporated into this alternative embodiment described below.
- the system 500 includes an ultrasonic material delivery apparatus 510 that may apply an application material 570 to an implantable device 180 and may include a conductive member 590 .
- the ultrasonic material delivery apparatus 510 may include an ultrasonic generator 320 and/or a material delivery apparatus 330 .
- the conductive member 590 may include an electrically conductive material such as platinum, gold, silver, copper, stainless steel, and/or other electrically conductive materials. As shown in FIG. 5 , the conductive member 590 may have an electric charge (shown as positive) applied to it. In the present embodiment, the ultrasonic material delivery apparatus 510 , the implantable device 180 , the conductive member 590 , and/or a combination of the three may have an electric charge, may be grounded, and/or may have an electric charge applied during application of the application material 570 .
- At least one of the ultrasonic material delivery apparatus 510 , the implantable device 180 , and the conductive member 590 in the present embodiment, has an electric charge or has an applied electric charge during application of the application material (i.e., in one configuration no more than two of the ultrasonic material delivery apparatus 510 , the implantable device 180 , and the conductive member 590 may be grounded during application of the application material).
- the implantable device 180 may be positioned between the ultrasonic material delivery apparatus 510 and the conductive member 590 .
- the application material 570 may be generally attracted to or generally repelled from the implantable device 180 and/or the conductive member 590 .
- the voltage potential difference between the application material 570 and the implantable device 180 and/or conductive member 590 may be sufficiently large to facilitate atomization of the application material 570 .
- system components include an ultrasonic material delivery device 510 , an implantable device 180 , and a conductive member 590 .
- system components may have an electric charge (i.e. may have an applied voltage or may retain a previously applied charge), two of the system components may have an electric charge with another system component grounded or uncharged, and/or one system component may have an electric charge with the remaining system components grounded or uncharged.
- the charged system components may all have the same electric charge (i.e. positive or negative) and/or at least one of the charged system components may have a different electric charge than the other charged system components.
- the charged system components may all have the same quantity of electric charge (i.e. whether positive or negative) or may differ in quantity of electric charge.
- the ultrasonic material delivery apparatus 510 may have a positive electric charge
- the implantable device 180 may have a negative electric charge
- the conductive member 590 may have a positive electric charge.
- the application material 570 may have a positive charge.
- the positively charged application material 570 in this example, may be generally attracted to the negatively charged implantable device 180 and generally repelled from the positively charged conductive member 590 .
- the electric charge as well as the quantity of electric charge of the various system components may affect the behavior (i.e. trajectory) of the application material 570 .
- the behavior of the application material 570 may be different if the implantable device 180 had an electric charge while the conductive member 590 was grounded compared to the implantable device 180 being grounded while the conductive member 590 had an electric charge.
- the application material 570 may have a generally more direct trajectory toward the implantable device 180 than in the example where the implantable device 180 is grounded and the conductive member 590 has an electric charge.
- the trajectory of the application material 570 may be more direct with respect to the implantable device 180 if the quantity of electric charge of the conductive member 590 were larger than if the quantity of electric charge of the conductive member 590 were smaller.
- Which system components may have an electric charge or be grounded, the position (i.e. location and/or orientation) of the system components, as well as the quantity of electric charge of the charged system components may be generally selected based on a desired application material 570 trajectory.
- FIG. 6 illustrates a further embodiment of a method 600 for applying an application material to an implantable device, in accordance with the present invention.
- the method 600 may be used in conjunction with components of the systems 100 , 300 , 500 described in connection with FIGS. 1 , 3 , and 5 and/or any other system for applying an application material to an implantable device described herein.
- the ultrasonic material delivery apparatus may include an ultrasonic generator 320 and/or a material delivery apparatus 330 , which may be selectively electrically isolated from each other.
- the method 600 of this further embodiment may be functionally similar to that of the methods 200 , 400 previously described above and shown in FIGS. 2 and 4 in most respects, wherein certain features will not be described in relation to this further embodiment wherein those method components may be performed in the manner as described above and are hereby incorporated into this alternative embodiment described below.
- An implantable device may be positioned between an ultrasonic material delivery apparatus and a conductive member, as represented by block 602 .
- Positioning an implantable device between an ultrasonic material delivery apparatus and a conductive member may include orienting the implantable device between an ultrasonic material delivery apparatus and a conductive member.
- a stent may be positioned such that it is about 30 mm from a nozzle of an ultrasonic material delivery apparatus and near the conductive member and/or may be oriented perpendicular to the application material being applied.
- an electric charge may be applied to the ultrasonic material delivery apparatus, the implantable device, and/or the conductive member.
- no more than two of the ultrasonic material delivery apparatus, the implantable device, and conductive member may be grounded.
- Application material may then be applied to the implantable device, as represented by block 604 .
- FIG. 7 illustrates a block diagram of a still further embodiment of a system 700 for applying an application material 770 to an implantable device 180 , in accordance with the present invention.
- the system 700 of this still further embodiment may be functionally similar to that of the systems 100 , 300 , 500 previously described above and shown in FIGS. 1 , 3 , and 5 in many respects, wherein certain features will not be described in relation to this still further embodiment wherein those components may function in the manner as described above and are hereby incorporated into this alternative embodiment described below.
- the system 700 includes an ultrasonic material delivery apparatus 710 that may apply an application material 770 to an implantable device 180 and may include a conductive member 790 .
- the ultrasonic material delivery apparatus 710 may include an ultrasonic power generator 722 , a transducer 724 , a housing 732 , a nozzle body 734 , a nozzle holder 736 , an ultrasonic transducer horn 738 , a pressure source 740 , an application material reservoir 750 , and/or an application material delivery apparatus 760 .
- the system 700 may include an ultrasonic generator.
- the ultrasonic generator may include an ultrasonic power generator 722 and at least one transducer 724 .
- the ultrasonic power generator 722 may generate high frequency electrical energy. High frequency electrical energy may be generated in the range, for example, from about 20 kHz to about 120 kHz. The frequency may be determined based on the characteristics of the nozzle body 734 and/or ultrasonic horn 738 .
- the ultrasonic power generator 722 may be in electrical communication with at least one transducer 724 .
- the at least one transducer 724 may convert the electrical energy generated by the ultrasonic power generator 722 into mechanical (i.e. vibration) energy.
- the transducers 724 may include piezoelectric transducers to facilitate in atomizing the application material 770 .
- the housing 732 may house the nozzle body 734 .
- the housing 732 may be connected to the nozzle holder 736 .
- the nozzle holder 736 may be used to position the ultrasonic material delivery apparatus 710 with respect to the implantable device 180 and/or conductive member 790 .
- the material delivery apparatus may include both an application material delivery apparatus 760 and a nozzle body 734 and ultrasonic horn 738 .
- the nozzle body 734 and ultrasonic horn 738 may be in fluid communication with the application material reservoir 750 and a pressure source 740 .
- the nozzle body 734 and/or the ultrasonic horn 738 may be in fluid communication with a pressure source 740 .
- the pressure source 740 in the present embodiment, may include an air pressure source.
- the pressure source 740 may generate a pressurized fluid that may be shaped and/or directed by the nozzle body 734 and/or the ultrasonic horn 738 .
- the pressure source 740 in the present embodiment, may generate a low-pressure air stream.
- ultrasonic horn 738 may be hollow with the gas from pressure source 740 passing through it.
- the application material delivery apparatus 760 may be connected to an application material reservoir 750 .
- the application material reservoir 750 may include a pump, pressurized reservoir, gravity system, and/or other delivery mechanism to direct the application material 770 to the application material delivery apparatus 760 .
- the application material delivery apparatus 760 may include a hypotube.
- the application material delivery apparatus 760 may deliver the application material 770 to the ultrasonic horn 738 to facilitate atomization of the application material 770 .
- the application material delivery apparatus 760 may have an electric charge and/or be grounded.
- the application material delivery apparatus 760 may be selectively electrically isolated from the ultrasonic power generator 722 .
- which system components may have an electric charge or be grounded as well as the quantity of electric charge of the charged system components may be generally selected based on a desired application material 770 trajectory.
- FIG. 8 illustrates a still further embodiment of a method 800 for applying an application material to an implantable device, in accordance with the present invention.
- the method 800 may utilize systems for applying a coating to an implantable device such as the systems 100 , 300 , 500 , 700 previously described above and shown in FIGS. 1 , 3 , 5 , and 7 .
- Components of these systems 100 , 300 , 500 , 700 may include an ultrasonic material delivery apparatus 110 (or components of an ultrasonic material delivery apparatus 310 or 710 such as an application material delivery apparatus 760 , a transducer 724 , an ultrasonic power generator 722 , and/or other system components), an implantable device 180 , and/or a conductive member 590 .
- the method 800 of this still further embodiment may be functionally similar to that of the methods 200 , 400 , 600 previously described above and shown in FIGS. 2 , 4 , and 6 in most respects, wherein certain features will not be described in relation to this still further embodiment wherein those method components may be performed in the manner as described above and are hereby incorporated into this alternative embodiment described below.
- An electric charge may be applied to a component of a system for applying a coating to an implantable device, as represented by block 802 .
- the electric charge applied to a component of a system for applying a coating to an implantable device may be applied before and/or maintained during application of the application material.
- an electric charge may be applied to an application material delivery apparatus during application of the application material.
- the implantable device may be positioned relative to an ultrasonic material delivery apparatus, as represented by block 804 .
- the implantable device may be positioned between the ultrasonic material delivery apparatus and a conductive member, as represented by block 806 .
- Ultrasonic energy may be applied to an application material using an ultrasonic generator, as represented by block 808 .
- Application material may be applied to the implantable device, as represented by block 810 .
- FIG. 9 illustrates a block diagram of an even further embodiment of a system 900 for applying an application material 970 to an implantable device 180 , in accordance with the present invention.
- the system 900 of this embodiment may be functionally similar to that of systems 100 , 300 , 500 , 700 previously described above and shown in FIGS. 1 , 3 , 5 , and 7 in many respects. As such, certain features will not be described in relation to this embodiment wherein those components may function in the manner as described above and are hereby incorporated into this alternative embodiment described below. Like structures or components are give like reference numerals.
- the system 900 includes an ultrasonic material delivery apparatus 910 that may apply an application material 970 to an implantable device 180 and may include a conductive member 990 .
- the ultrasonic material delivery apparatus 910 may include an ultrasonic generator 320 and/or a material delivery apparatus 330 .
- the conductive member 990 may include an electrically conductive material such as platinum, gold, silver, copper, stainless steel, and/or other electrically conductive materials. As shown in FIG. 9 , the conductive member 990 may have an electric charge (shown as positive) applied to it.
- the ultrasonic material delivery apparatus 910 , the implantable device 180 , the conductive member 990 , and/or a combination of the three may have an electric charge, may be grounded, and/or may have an electric charge applied during application of the application material 970 .
- At least one of the ultrasonic material delivery apparatus 910 , the implantable device 180 , and the conductive member 990 in the present embodiment, has an electric charge or has an applied electric charge during application of the application material (i.e., in one configuration no more than two of the ultrasonic material delivery apparatus 910 , the implantable device 180 , and the conductive member 990 may be grounded during application of the application material).
- the application material 970 may be generally attracted to or generally repelled from the implantable device 180 and/or the conductive member 990 .
- the voltage potential difference between the application material 970 and the implantable device 180 and/or conductive member 990 may be sufficiently large to facilitate atomization of the application material 970 .
- the conductive member 990 may be positioned between the ultrasonic material delivery apparatus 910 and the implantable device 180 . In other embodiments, the ultrasonic material delivery apparatus 910 , the conductive member, and/or the implantable device 180 may be otherwise positioned.
- the conductive member 990 is illustrated in FIG. 9 as an annular ring. In other embodiments, the conductive member 990 may be tubular, cylindrical, spherical, rectangular, and/or otherwise shaped to perform the desired function of aiding to direct the flow of application material to the implantable device.
- the conductive member 990 may perform additional functions.
- the conductive member 990 may include a focusing assembly that uses a deflecting fluid to focus the trajectory of the application material 970 . Deflecting a fluid path using a focusing assembly may be accomplished as disclosed in U.S. Patent Application No. 61/015,137, filed Dec. 19, 2007, and entitled “METHODS FOR APPLYING AN APPLICATION MATERIAL TO AN IMPLANTABLE DEVICE”, which is incorporated herein by reference in its entirety.
- the conductive member 990 may include an annular focusing jet to deflect the trajectory of the application material 970 .
- which system components may have an electric charge or be grounded as well as the magnitude of electric charge of the charged system components may be generally selected based on a desired application material 970 trajectory.
- FIG. 10 illustrates a schematic representation of an embodiment of a system 1000 for applying an application material 1070 to an implantable device 1080 , in accordance with the present invention.
- the system 1000 of this embodiment may be functionally similar to that of systems 100 , 300 , 500 , 700 , 900 previously described above and shown in FIGS. 1 , 3 , 5 , 7 , and 9 in many respects, wherein certain features will not be described in relation to this embodiment wherein those components may function in the manner as described above and are hereby incorporated into this alternative embodiment described below.
- Like structures or components are give like reference numerals.
- the system 1000 may include an ultrasonic material delivery apparatus 1010 that may apply an application material 1070 to an implantable device 1080 .
- the delivery or loading of the application material 1070 to the implantable device 1080 can be varied through use of a controller 1002 , the ultrasonic material delivery apparatus 1010 , a positioning assembly 1012 , and/or other components.
- the controller 1002 can be programmed with the structural configuration of the implantable device 1080 and control delivery or loading the application material 1070 through controlling the operation of the ultrasonic material delivery apparatus 1010 , the positioning assembly 1012 , and/or other components.
- Other components may include a focusing assembly that may deflect or change a spray pattern of the application material 1070 . In this manner, the invention reduces or eliminates webbing and bridging of application material across openings or gaps within the structure of the prosthesis and minimizes waste.
- the positioning assembly 1012 can include a driver assembly 1020 that creates relative movement between the implantable device 1080 and the ultrasonic material delivery apparatus 1010 .
- the positioning assembly 1012 can also include a rotation assembly 1013 that creates rotational movement of the implantable device 1080 and/or a holder 1014 configured to support and/or rotate the implantable device 1080 .
- the controller 1002 in communication with the driver assembly 1020 can define a dispensing path of relative movement between the ultrasonic material delivery apparatus 1010 and the rotation assembly 1013 .
- the controller 1002 can also communicate with the ultrasonic material delivery apparatus 1010 for selectively dispensing application material 1070 in a selected format along the dispensing path onto a selected portion of the implantable device 1080 supported by the holder 1014 .
- the rotation assembly 1013 supporting the implantable device 1080 is longitudinally moveable while the ultrasonic material delivery apparatus 1010 remains stationary during dispensing of application material 1070 .
- the rotation assembly 1013 supporting the implantable device 1080 may remain longitudinally stationary (although may still rotate) while the ultrasonic material delivery apparatus 1010 moves along the dispensing path.
- both the rotation assembly 1013 and ultrasonic material delivery apparatus 1010 are longitudinally moveable.
- the system 1000 can include a detector or sensor to detect when the ultrasonic material delivery apparatus 1010 is aligned with the selected portions of the implantable device 1080 .
- a detector or sensor can be an optical detector, e.g., linear array detector or infrared detector, ultrasound probe, temperature probe, camera, capacitance meter, electrometer, hall-effect probe, and the like, or any other sensor or detector known in the art for detection.
- the system 1000 can include a focusing assembly to aid delivery or loading application material 1070 through varying or changing the spray pattern of the application material 1070 .
- the focusing assembly may include at least one focusing jet, an annular jet, and/or other focusing assembly components.
- the positioning assembly 1012 can further include a longitudinal driver 1018 .
- the rotation assembly 1013 can likewise further include a rotating driver 1016 .
- the holder 1014 may be rotated through the rotation driver 1016 , which can include a motor.
- the rotating driver 1016 can be activated to produce a constant angular velocity on the implantable device 1080 during application material delivery.
- the longitudinal driver 1018 can control advancement of the implantable device 1080 longitudinally past the ultrasonic material delivery apparatus 1010 .
- the longitudinal driver 1018 can include a motor.
- application material 1070 can be loaded or delivered to an implantable device 1080 in a controlled manner.
- the system 1000 enables and facilitates relative movement between the material application apparatus 1010 and the implantable device 1080 to define a dispensing path along which the application material 1070 can be selectively dispensed.
- the positioning assembly 1012 and/or rotation assembly 1013 may aid the delivery or loading of the application material 1070 through varying or changing the spray pattern of the application material 1070 .
- the application material 1070 is selectively dispensed from the ultrasonic material delivery apparatus 1010 to a predetermined portion of the implantable device 1080 along the dispensing path.
- the dispensing path can include, for example, a sequential series of linear parallel passes that traverse back and forth along one axis of the implantable device 1080 .
- the relative motion can be continued in a linear manner between forward and backward or right to left and left to right or upward and downward, depending on the frame of reference.
- a traversal or a pass can be completed when the relative motion reverses direction. That is, relative motion continues past the implantable device, and then decelerates, stops, reverses direction, and/or accelerates to a constant velocity.
- the system 1000 may adjust the position of the ultrasonic material delivery apparatus 1010 and/or implantable device 1080 relative to the ultrasonic material delivery apparatus 1010 can be changed or incremented to limit the possibility of application overlap, although a certain degree of overlap may be permitted.
- the dispensing path created by the relative motion of the ultrasonic material delivery apparatus 1010 and the implantable device 1080 can include a single continuous helix that wraps continuously around the implantable device tubular body and along the length of the implantable device 1080 .
- the dispensing path can include a non-continuous helix.
Abstract
Devices and methods for applying a coating to an implantable device are disclosed. A method for applying a coating to an implantable device is disclosed. The method includes positioning an implantable device relative to an ultrasonic material delivery apparatus. The ultrasonic material delivery apparatus includes an ultrasonic generator. At least one of the ultrasonic material delivery apparatus and the implantable device has a positive or negative electric charge. An application material is applied to the implantable device using the ultrasonic material delivery apparatus.
Description
- This application claims the benefit of and priority to U.S. Provisional Patent Application No. 61/015,126, filed Dec. 19, 2007, and entitled “Methods For Applying An Application Material To An Implantable Device” which is incorporated herein by reference in its entirety. This application also incorporates U.S. Provisional Patent Application No. 61/015,137, filed Dec. 19, 2007, and entitled “Methods For Applying An Application Material To An Implantable Device”, by reference in its entirety.
- The present invention relates generally to medical devices, and more particularly to methods for applying an application material to an implantable device.
- Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart disease. This procedure generally entails introducing a catheter assembly into the cardiovascular system of a patient via the brachial or femoral artery and advancing the catheter assembly through the coronary vasculature until a balloon portion thereon is positioned across an occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress against the atherosclerotic plaque of the lesion to remodel the vessel wall. Subsequently, the balloon is deflated to allow the catheter assembly to be withdrawn from the vasculature.
- While PTCA is widely used, it suffers generally from two unique problems. First, the blood vessel may suffer acute occlusion immediately after or within the initial hours after the dilation procedure. Such occlusion is referred to as “abrupt closure.” Abrupt closure occurs in approximately five percent of cases in which PTCA is employed. The primary mechanisms of abrupt closures are believed to be elastic recoil, vasospasm, arterial dissection, and/or thrombosis. The second problem associated with this procedure is the re-narrowing of an artery after an initially successful angioplasty. This re-narrowing is referred to as “restenosis,” which typically occurs within the first six months after angioplasty. Restenosis is believed to be due to, among other things, the proliferation and migration of cellular components from the arterial wall, as well as through geometric changes in the arterial wall referred to as “remodeling.”
- To reduce occlusion of the artery, and the development of thrombosis and/or restenosis, an expandable interventional device or prosthesis, one example of which includes a stent, may be implanted in the lumen to maintain the vascular patency. Additionally, to better effectuate the treatment of such vascular disease, it may be preferable to load an intraluminal device or prosthesis with one or more beneficial agents, such as antiproliferatives, for delivery to a lumen. One commonly applied technique for the local delivery of a drug is through the use of a polymeric carrier coated onto the surface of a stent, as disclosed in Berg et al., U.S. Pat. No. 5,464,650, the disclosure of which is incorporated herein by reference thereto. Such conventional methods and products generally have been considered satisfactory for their intended purpose.
- However, implantable devices, such as stents may be difficult to coat without webbing, cobwebs, or other defects due to their generally intricate geometry. They may also be difficult to uniformly coat (i.e. on the ablumenal, luminal, and sidewall surfaces). Because of these challenges, many commercialized drug eluting stents are being coated by a spray process. However, spray coating may suffer generally from the following: reduced coating speed, reproducibility, and/or coating efficiency (i.e. the amount of material sprayed actually coating the device).
- Accordingly, it may be desirable to provide methods for applying an application material to an implantable device.
- Methods for applying an application material to an implantable device are disclosed. In one embodiment, a method for applying a coating to an implantable device is disclosed. The method includes positioning an implantable device relative to an ultrasonic material delivery apparatus. The ultrasonic material delivery apparatus includes an ultrasonic generator. At least one of the ultrasonic material delivery apparatus and the implantable device has a positive or negative electric charge. The method includes applying an application material to the implantable device using the ultrasonic material delivery apparatus.
- In another embodiment, a method for applying a coating to an implantable device is disclosed. The method includes positioning an implantable device between a conductive member and an ultrasonic material delivery apparatus. The ultrasonic material delivery apparatus includes an ultrasonic generator. The conductive member has either a positive or a negative charge. The method includes applying an application material to the implantable device using the ultrasonic material delivery apparatus.
- In another embodiment, a method for applying a coating to an implantable device is disclosed. The method includes positioning a stent between an ultrasonic material delivery apparatus and a grounded conductive member. The ultrasonic material delivery apparatus includes an ultrasonic generator. At least one of the ultrasonic material delivery apparatus and the stent has a positive or negative electric charge. The method includes applying ultrasonic energy to an application material using the ultrasonic generator. The method also includes applying the application material to the stent using the ultrasonic material delivery apparatus.
- In a further embodiment, a method for applying a coating to an implantable device is disclosed. The method includes positioning a conductive member between a stent and an ultrasonic material delivery apparatus. The ultrasonic material delivery apparatus includes an ultrasonic generator. The conductive member has a positive or a negative charge. The method includes applying ultrasonic energy to an application material using the ultrasonic generator. The method also includes applying the application material to the stent using the ultrasonic material delivery apparatus.
- In some embodiments, the ultrasonic material delivery device includes a material delivery device. At least one of the material delivery device and the implantable device has a positive or negative electric charge. The material delivery device, in further embodiments, is selectively electrically isolated from the ultrasonic generator. The material delivery apparatus, in still further embodiments, combines ultrasonic atomization with a flowing gas stream.
- The ultrasonic material delivery apparatus, in some embodiments, has a positive or negative electric charge and the positive or negative electric charge is of sufficient strength to facilitate atomization of the application material.
- The implantable device, in some embodiments, is positioned between the ultrasonic material delivery apparatus and a conductive member. The conductive member, in further embodiments, has a positive or a negative charge or is grounded.
- The conductive member, in some embodiments, is positioned between the implantable device and the ultrasonic material delivery apparatus. The conductive member, in further embodiments, has a positive or a negative charge. In still further embodiments, the conductive member is an annular shaped ring.
- In some embodiments, the implantable device, the ultrasonic material delivery apparatus, or the conductive member has a difference in electrical potential of less than or equal to about 100 kV in either a positive or negative polarity. Both the implantable device and the ultrasonic material delivery apparatus, in further embodiments, have either a positive or a negative charge.
- Applying the application material to the implantable device using the ultrasonic material delivery apparatus, in some embodiments, includes applying ultrasonic energy to the application material using the ultrasonic generator. In further embodiments, the applied ultrasonic energy is sufficient to facilitate atomization of the application material.
- The application material, in some embodiments, includes a radiopaque material, at least one bioactive agent that is an anti-proliferative, anti-inflammatory, antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic, antibiotic, antiallergic or antioxidant drug, a durable and/or biodegradable polymer, and/or a solvent. The implantable device, in further embodiments, is a closure element and/or a stent.
- It is to be understood that both the foregoing general description and the following detailed description are exemplary and are intended to provide further explanation of the invention claimed.
- The accompanying Figures, which are incorporated in and constitute part of this specification, are included to illustrate and provide a further understanding of the method and system of the invention. Together with the description, the Figures serve to explain the principles of the invention.
- In order to describe the manner in which the above-recited and other advantages and features of the invention can be obtained, a more particular description of the invention briefly described above will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. Understanding that these drawings depict only typical embodiments of the invention and are not therefore to be considered to be limiting of its scope, the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings.
-
FIG. 1 illustrates a block diagram of an embodiment of a system for applying an application material to an implantable device, in accordance with the present invention. -
FIG. 2 illustrates an embodiment of a method for applying an application material to an implantable device, in accordance with the present invention. -
FIG. 3 illustrates a block diagram of another embodiment of a system for applying an application material to an implantable device, in accordance with the present invention. -
FIG. 4 illustrates another embodiment of a method for applying an application material to an implantable device, in accordance with the present invention. -
FIG. 5 illustrates a block diagram of a further embodiment of a system for applying an application material to an implantable device, in accordance with the present invention. -
FIG. 6 illustrates a further embodiment of a method for applying an application material to an implantable device, in accordance with the present invention. -
FIG. 7 illustrates a block diagram of a still further embodiment of a system for applying an application material to an implantable device, in accordance with the present invention. -
FIG. 8 illustrates a still further embodiment of a method for applying an application material to an implantable device, in accordance with the present invention. -
FIG. 9 illustrates a block diagram of an even further embodiment of a system for applying an application material to an implantable device, in accordance with the present invention. -
FIG. 10 illustrates a schematic representation of an embodiment of a system for applying an application material to an implantable device, in accordance with the present invention. - It should be noted that the figures are not drawn to scale and that elements of similar structures or functions are generally represented by like reference numerals for illustrative purposes throughout the figures. It also should be noted that the figures are only intended to facilitate the description of embodiments of the present invention.
- In one embodiment, a coating nozzle for an implantable device, such as a stent, is disclosed. The coating solution may be atomized by a combination of ultrasonic energy and application of an electric field. The ultrasonic energy is present to atomize the solution while the electrical field is applied to the nozzle primarily to impart an electric charge to the droplets so that they are attracted to a grounded part to be coated. However, if the applied electric field is high enough, it may also facilitate in the atomization.
- Other embodiments include applying an electrical field to an ultrasonic material delivery apparatus, an implantable device, and/or a conductive member. In some embodiments, the implantable device may be placed between the ultrasonic delivery apparatus and the conductive member. In other embodiments, the conductive member may be placed between the ultrasonic delivery apparatus and the implantable device. The conductive member may be a single electrode, several electrodes that are interconnected, and/or a shaped electrode, such as a tubular, cylindrical, spherical, rectangular, and/or otherwise shaped electrode.
- Further embodiments include grounding no more than two of the ultrasonic material delivery apparatus, the implantable device, and/or the conductive member. Still further embodiments include grounding either the ultrasonic material delivery apparatus or the implantable device. By setting up an electric field between the ultrasonic material delivery apparatus and the implantable device, the application material may generally follow a curved trajectory towards the implantable device, thereby generally increasing the coating efficiency.
- Increased coating efficiency may be achieved by setting up an electric field between the ultrasonic material delivery apparatus and the conductive member and positioning the implantable device between the ultrasonic delivery apparatus and the conductive member. Due to the position of the conductive member, the application material may generally follow a curved trajectory towards the implantable device, thereby generally increasing the coating efficiency. In another embodiment, a focusing of application material droplets towards the implantable device may be achieved rather than attracting the droplets to the implantable device. Focusing the application material droplets may be achieved by positioning the conductive member between the ultrasonic delivery apparatus and the implantable device, and applying an electrical potential of the same sign to both the conductive member and the ultrasonic delivery apparatus. Use of a properly designed and positioned conductive member may repel application material droplets that are not on a trajectory toward the implantable device, and redirect them on a trajectory towards the implantable device.
- These results, whether individually or collectively, can be achieved, according to one embodiment of the present invention, by employing methods, systems, and/or apparatus as shown in the figures and described in detail below.
- Turning now to the drawings,
FIG. 1 illustrates a block diagram of an embodiment of asystem 100 for applying anapplication material 170 to animplantable device 180, in accordance with the present invention. Thesystem 100 includes an ultrasonic material delivery apparatus 110 that may apply anapplication material 170 to animplantable device 180. Theapplication material 170 may include beneficial agents, imaging materials, solvents, and/or other application materials. - Beneficial agents may include analgesics, antipyretics, antiasthmatics, antibiotics, antidepressants, antidiabetics, antifungal agents, antihypertensive agents, anti-inflammatories including non-steroidal and steroidal, antineoplastics, antianxiety agents, immunosuppressive agents, antimigraine agents, sedatives, hypnotics, antianginal agents, antipsychotic agents, antimanic agents, antiarrhythmics, antiarthritic agents, antigout agents, anticoagulants, thrombolytic agents, antifibrinolytic agents, hemorheologic agents, antiplatelet agents, anticonvulsants, antiparkinson agents, antihistamines, anti-restenosis agents, antipruritics, agents useful for calcium regulation, antibacterial agents, antiviral agents, antimicrobials, anti-infectives, bronchodilators, steroidal compounds and hormones, or combinations thereof. Preferably, the active agent includes at least one of rapamycin, rapamycin analog, sirolimus, everolimus, zotarolimus, 40-epi-(Nl-tetrazolyl)-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, Biolimus A9 (Biosensors International, Singapore), deforolimus, AP23572 (Ariad Pharmaceuticals), temsirolimus, novolimus, myolimus, dexamethasone, dexamethasone acetate, dexmethasone phosphate, momentasone, cortisone, cortisone acetate, hydrocortisone, prednisone, prednisone acetate, betamethasone, betamethasone acetate, estradiol, acetaminophen, ibuprofen, naproxen, sulidac, heparin, taxol, paclitaxel, and/or combinations thereof.
- Imaging materials may include materials, such as radiopaque materials. Examples of radiopaque materials may include high-density materials such as gold, platinum, platinum/iridium, tantalum, tungsten, gadolinium salts, gadolinium complexes, bismuth compounds, barium compounds, and/or other radiopaque materials. As used herein, the term radiopaque may include partial radiopacity as well as total radiopacity.
- Solvents may include methanol, ethanol isopropanol, n-propanol, isobutanol, sec-butanol, n-butanol, benzyl alcohol, alcohols, diethyl ether, tetrahydrofuran, 1,4-dioxane, ethers, butyl acetate, isopropyl acetate, ethyl acetate, methyl acetate, esters, acetone, 4-butanone, cyclopentanone, cyclohexanone, ketones, 1-methoxy-2-propanol, diacetone alcohol, methylene chloride, chloroform, carbon tetrachloride, 1,1,1-trichloroethane, trichloroethylene, chlorobenzene, freons, pentane, hexane, cyclohexane, n-heptane, n-octane, benzene, toluene, o-xylene, p-xylene, m-xylene, dimethylenformamide, formamide, dimethylacetamide, dimethylsulfoxide, sulfolane, hexamethyl phosphorustriamide, n-methylpyrrolidone, 1,1,1-trifluoroethanol, hexafluoroisopropanol, water, and/or other solvents.
- Other application materials may include polymeric materials comprised of phosphorylcholines, phosphorylcholine linked macromolecules, polyolefins, poly(meth)acrylates, polyurethanes, polyesters, polyanhydrides, polyphosphazenes, polyacrylates, acrylic polymers, poly(lactide-co-glycolides) (PLGA), polylactic acids (PLA), poly(hydroxybutyrates), poly(hydroxybutyrate-co-valerates), polydioxanones (PDO), polyorthoesters, polyglycolic acids (PGA), polycaprolactones (PCL), poly(glycolic acid-co-trimethylene carbonates), polyphosphoesters, polyphosphoester urethanes, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), polyalkylene oxalates, polyiminocarbonates, aliphatic polycarbonates, fibrins, fibrinogens, celluloses, starchs, collagens, polycarbonate urethanes, polyisoprenes, polyisobutylenes, polybutadienes, polyethylenes, plasticized polyethylene terephthalates, polyethylene terepthalates, polymethylmethacrylates, poly(ethylene-co-ethylacrylates), poly(ethyl hexylacrylates), plasticized poly(ethylene-co-vinylacetates, polyvinyl acetates, poly(ethylene-co-vinyl acetates), poly(ethylene-co-vinyl alcohols), polyvinyl alcohols, cross-linked polyvinyl alcohols, cross-linked polyvinyl butyrates, polyvinylbutyrates, polybutylmethacrylates, polyvinyl chlorides, polyvinyl fluorides, polyvinylidene fluorides, poly(vinylidene fluoride-co-hexafluoropropylene), poly(vinylidene fluoride-co-chlorotrifluoroethylene), ethylene vinylchloride copolymers, silicones, polysiloxanes, substituted polysiloxanes, polyethylene oxides, polyethylene glycols (PEG), polybutylene terepthalate-co-PEG, PCL-co-PEG, PLA-co-PEG, polyvinyl acetals, polyvinyl acetates, polyamides, polyvinyl pyrrolidones, polyacrylamides, polyvinyl esters, copolymers thereof, polymer derivatives thereof, and/or combinations thereof.
-
Implantable devices 180 may include endoprostheses, drug delivery stents, drug delivery catheters, stent-grafts, grafts, drug delivery balloons, guidewires, orthopedic implants, PFO closure devices, pacemaker leads, dental implants, fixation screws, indwelling catheters, ocular implants, pharmacotherapeutic implants, blood-contacting components of extracorporeal devices, staples, filters, needles, tubes, coils, wires, clips, screws, sensors, plates, conduits, portions thereof, closure elements for engaging tissue, combinations thereof, and/or other implantable devices. - In one embodiment, the implantable device may include an endoprosthesis for controlling the release of an active agent therefrom. Such an endoprosthesis can include the following: a supporting metal structure configured and dimensioned to be used within a body of a human; a porous body disposed on and at least partially covering the supporting metal structure, said porous body including a first biocompatible material having a plurality of pores; a therapeutically effective amount of an active agent disposed within said pores, said therapeutically effective amount of the active agent being capable of treating and/or preventing a disease; an elution rate controlling matrix disposed within the porous body so as to contain said active agent within said pores, said matrix material including a polymeric biocompatible material that at least partially controls an elution rate of the active agent from the pores; and said pores each having a dimension that is configured to at least partially determine said elution rate.
- In one embodiment, the implantable device may include a stent for controlling the release of an active agent therefrom. Such a stent can include the following: a superelastic metal structure configured and dimensioned as a stent to be used within a lumen of an animal; a porous body disposed on and at least partially covering the superelastic metal structure, said porous body including a first biocompatible material having a plurality of pores; a therapeutically effective amount of an active agent disposed within at least a portion of the pores, said therapeutically effective amount of the active agent being capable of treating and/or preventing a disease; and an elution rate controlling matrix disposed on at least one surface of the porous body so as to contain the active agent within said at least a portion of the pores, said matrix material including a second biocompatible material that controls an elution rate of the active agent from the pores. Optionally, the porous body is integrated with the supporting structure.
- In another embodiment, the implantable device may include an endoprosthesis for controlling the release of an active agent therefrom. Such an endoprosthesis may include a supporting metal structure configured and dimensioned to be used within a body of a human, a coating body disposed on and at least partially covering the supporting metal structure, the coating body including a first biocompatible polymeric material having a largely homogeneous structure, a therapeutically effective amount of an active agent combined with the biocompatible polymeric material to make a largely homogeneous composition, the therapeutically effective amount of the active agent being capable of treating and/or preventing a disease, and the biocompatible polymeric material being either a durable or a biodegradable polymer.
- In the present embodiment, the ultrasonic material delivery apparatus 110 and/or the
implantable device 180 may have a positive or negative electric charge when applying theapplication material 170. Having an electric charge may include having an electric charge (i.e. positive, negative, or zero) with respect to a reference point. A reference point may include, for example, a ground. In some embodiments, the electric charge may be directly applied to a component by applying a voltage potential to the component while applying theapplication material 170. In further embodiments, a component may be grounded before and/or during the application of theapplication material 170. Grounding a component may include, for example, putting the component in electrical communication with a ground. - Typically, if the ultrasonic material delivery apparatus 110 has an electric charge, the
application material 170 may have the same electric charge as the ultrasonic material delivery apparatus 110. For example, if the ultrasonic material delivery apparatus 110 has a positive electric charge the application material may also have a positive electric charge. - In embodiments where the
application material 170 has an electric charge, theapplication material 170 may be generally attracted to or generally repelled from theimplantable device 180. In some embodiments, the voltage potential between theapplication material 170 and theimplantable device 180 may be sufficiently large to facilitate atomization of theapplication material 170. - In one example, the ultrasonic material delivery apparatus 110 may have a positive electric charge and the
implantable device 180 may have a negative electric charge. When the ultrasonic material delivery apparatus 110 applies theapplication material 170 to theimplantable device 180, theapplication material 170 may have a positive charge. The positively chargedapplication material 170, in this example, may be generally attracted to the negatively chargedimplantable device 180. - In embodiments where the electric charge of the
implantable device 180 is generally opposite the electric charge of the ultrasonic material delivery apparatus 110, theapplication material 170 may be generally more attracted to theimplantable device 180 than in embodiments where only the ultrasonic material delivery apparatus 110 or theimplantable device 180 have an electric charge. In embodiments where the electric charge of theimplantable device 180 is generally opposite the electric charge of the ultrasonic material delivery apparatus 110 and where the opposite electric charges are relatively large, theapplication material 170 may be generally more attracted to theimplantable device 180 than where the opposite electric charges are relatively small. - In another example, the ultrasonic material delivery apparatus 110 may have the same or similar electric charge as the implantable device 180 (i.e. both generally positive or both generally negative). When the ultrasonic material delivery apparatus 110 applies the
application material 170 to theimplantable device 180, theapplication material 170 may have the same or similar electric charge as theimplantable device 180. Theapplication material 170, in this example, may be generally repelled from the same or similarly chargedimplantable device 180. In embodiments where the electric charge of theimplantable device 180 is generally similar to the electric charge of the ultrasonic material delivery apparatus 110 and where the similar electric charges are relatively large, theapplication material 170 may be generally more repelled by theimplantable device 180 than where the similar electric charges are relatively small. - Repelling the
application material 170 may be useful when it is desired to only apply theapplication material 170 to a surface closest to the ultrasonic material delivery apparatus 110 (i.e. the abluminal surface of a stent). For example, theapplication material 170 may have a velocity that is sufficient to overcome any repulsing force from the opposing electric charges and apply theapplication material 170 to a surface closest to the ultrasonic material delivery apparatus 110, but the velocity may be insufficient to overcome the repulsing force from the opposing electric charges to apply theapplication material 170 to another surface (i.e. the luminal surface of a stent). - In some embodiments, the ultrasonic material delivery apparatus 110 or the
implantable device 180 may have an electric charge while the other device may be grounded. For example, if the ultrasonic material delivery apparatus 110 has an electric charge and theimplantable device 180 is grounded, when the ultrasonic material delivery apparatus 110 applies theapplication material 170 to theimplantable device 180, theapplication material 170 may be more attracted to the groundedimplantable device 180 than to an implantable device that is not grounded. In another example, if the ultrasonic material delivery apparatus 110 is grounded and theimplantable device 180 has an electric charge, when the ultrasonic material delivery apparatus 110 applies theapplication material 170 to theimplantable device 180, the application material 170 (which may not have an electric charge because the ultrasonic material delivery apparatus 110 is grounded) may be more attracted to the chargedimplantable device 180 than to an implantable device that is not electrically charged. -
FIG. 2 illustrates an embodiment of amethod 200 for applying an application material to an implantable device, in accordance with the present invention. In the present embodiment, themethod 200 may be used in conjunction with components of thesystem 100 described in connection withFIG. 1 and/or any other system for applying an application material to an implantable device described herein. For example, the ultrasonic material delivery apparatus 110 and/or theimplantable device 180 may have a positive or negative electric charge. - An implantable device may be positioned relative to an ultrasonic material delivery apparatus, as represented by
block 202. Positioning an implantable device relative to an ultrasonic material delivery apparatus may include positioning the implantable device in a desired location and/or in a desired orientation. For example, a stent may be positioned about 30 mm from a nozzle of an ultrasonic material delivery apparatus and/or oriented perpendicular to the application material being applied. - In some embodiments, before and/or during the application of the application material to the implantable device, an electric charge may be applied to the ultrasonic material delivery apparatus and/or the implantable device. For example, the system component may be charged before applying the application material, but not during the application of the application material. In this example, the system component may nevertheless be charged by virtue of, for example, retaining the charge. In further embodiments, before applying the application material to the implantable device, the ultrasonic material delivery apparatus and/or the implantable device may be grounded.
- An application material may be applied to the implantable device, as represented by
block 204. Applying the application material to the implantable device may include moving the implantable device and/or the ultrasonic material delivery apparatus with respect to each other. For example, the ultrasonic material delivery apparatus may move along a length and/or width of the implantable device and the implantable device may rotate to facilitate a generally uniform application of the application material. -
FIG. 3 illustrates a block diagram of another embodiment of asystem 300 for applying anapplication material 370 to animplantable device 180, in accordance with the present invention. Thesystem 300 of this other embodiment may be functionally similar to that of thesystem 100 previously described above and shown inFIG. 1 in most respects, wherein certain features will not be described in relation to this other embodiment wherein those components may function in the manner as described above and are hereby incorporated into this alternative embodiment described below. - The
system 300 includes an ultrasonic material delivery apparatus 310 that may apply anapplication material 370 to animplantable device 180. The ultrasonic material delivery apparatus 310, in the present embodiment, may include anultrasonic generator 320. Theultrasonic generator 320 may include an ultrasonic power generator (not shown) and at least one transducer (not shown, but see description ofFIG. 7 ). Theultrasonic generator 320 may generate ultrasonic energy to facilitate atomization of theapplication material 370. For example, theultrasonic generator 320 may generate a transverse standing wave along the length, or at the end of, the nozzle. - The ultrasonic material delivery apparatus 310, in the present embodiment, may include a
material delivery apparatus 330. Thematerial delivery apparatus 330 may include, for example, a nozzle body and/or nozzle stem (see, for example,FIG. 7 ). - The ultrasonic material delivery apparatus 310 and/or the
implantable device 180 may have a positive or negative electric charge. The ultrasonic material delivery apparatus 310 or theimplantable device 180 may be grounded. - In the present embodiment, the
material delivery apparatus 330 may be grounded before and/or during application of the application material. In other embodiments, thematerial delivery apparatus 330 may have an electric charge before and/or during application of the application material. Thematerial delivery apparatus 330, in the present embodiment, may be selectively electrically isolated from theultrasonic generator 320. For example, theultrasonic generator 320 and/or thematerial delivery apparatus 330 may be electrically insulated. - The
implantable device 180 may be grounded, as shown inFIG. 3 . However, although the optional ground lines connected to thematerial delivery apparatus 330 and theimplantable device 180 indicate that both may be optionally grounded, only theimplantable device 180 or the ultrasonic material delivery apparatus 310 (including the material delivery apparatus 330) may be grounded, in the present embodiment, before and/or during application of theapplication material 370. -
FIG. 4 illustrates another embodiment of amethod 400 for applying an application material to an implantable device, in accordance with the present invention. In the present embodiment, themethod 400 may be used in conjunction with components of thesystems FIGS. 1 and 3 and/or any other system for applying an application material to an implantable device described herein. For example, themethod 400 may utilize one of thematerial delivery apparatus 330 and theimplantable device 180. - The
method 400 of this other embodiment may be functionally similar to that of themethod 200 previously described above and shown inFIG. 2 in most respects, wherein certain features will not be described in relation to this other embodiment wherein those method components may be performed in the manner as described above and are hereby incorporated into this alternative embodiment described below. - An implantable device may be positioned relative to an ultrasonic material delivery apparatus, as represented by
block 402. Ultrasonic energy may be applied to an application material using an ultrasonic generator, as represented byblock 404. The ultrasonic generator used may include theultrasonic generator 320 described above. The application material may be applied to the implantable device, as represented byblock 406. -
FIG. 5 illustrates a block diagram of a further embodiment of asystem 500 for applying anapplication material 570 to animplantable device 180, in accordance with the present invention. Thesystem 500 of this other embodiment may be functionally similar to that of thesystems FIGS. 1 and 3 in most respects, wherein certain features will not be described in relation to this further embodiment wherein those components may function in the manner as described above and are hereby incorporated into this alternative embodiment described below. - The
system 500 includes an ultrasonic material delivery apparatus 510 that may apply anapplication material 570 to animplantable device 180 and may include aconductive member 590. The ultrasonic material delivery apparatus 510 may include anultrasonic generator 320 and/or amaterial delivery apparatus 330. - The
conductive member 590 may include an electrically conductive material such as platinum, gold, silver, copper, stainless steel, and/or other electrically conductive materials. As shown inFIG. 5 , theconductive member 590 may have an electric charge (shown as positive) applied to it. In the present embodiment, the ultrasonic material delivery apparatus 510, theimplantable device 180, theconductive member 590, and/or a combination of the three may have an electric charge, may be grounded, and/or may have an electric charge applied during application of theapplication material 570. However, at least one of the ultrasonic material delivery apparatus 510, theimplantable device 180, and theconductive member 590, in the present embodiment, has an electric charge or has an applied electric charge during application of the application material (i.e., in one configuration no more than two of the ultrasonic material delivery apparatus 510, theimplantable device 180, and theconductive member 590 may be grounded during application of the application material). - In embodiments including a
conductive member 590, theimplantable device 180 may be positioned between the ultrasonic material delivery apparatus 510 and theconductive member 590. - Similar to the previous embodiments, in embodiments where the
application material 570,implantable device 180, and/or theconductive member 590 have an electric charge, theapplication material 570 may be generally attracted to or generally repelled from theimplantable device 180 and/or theconductive member 590. In some embodiments, the voltage potential difference between theapplication material 570 and theimplantable device 180 and/orconductive member 590 may be sufficiently large to facilitate atomization of theapplication material 570. - In systems where the system components include an ultrasonic material delivery device 510, an
implantable device 180, and aconductive member 590, various combinations of electrically charged, grounded, and uncharged system components may be used. For example all three system components may have an electric charge (i.e. may have an applied voltage or may retain a previously applied charge), two of the system components may have an electric charge with another system component grounded or uncharged, and/or one system component may have an electric charge with the remaining system components grounded or uncharged. In embodiments where at least two of the system components are electrically charged, the charged system components may all have the same electric charge (i.e. positive or negative) and/or at least one of the charged system components may have a different electric charge than the other charged system components. Furthermore, the charged system components may all have the same quantity of electric charge (i.e. whether positive or negative) or may differ in quantity of electric charge. - In one example, the ultrasonic material delivery apparatus 510 may have a positive electric charge, the
implantable device 180 may have a negative electric charge, and theconductive member 590 may have a positive electric charge. When the ultrasonic material delivery apparatus 510 applies theapplication material 570 to theimplantable device 180, theapplication material 570 may have a positive charge. The positively chargedapplication material 570, in this example, may be generally attracted to the negatively chargedimplantable device 180 and generally repelled from the positively chargedconductive member 590. - The electric charge as well as the quantity of electric charge of the various system components may affect the behavior (i.e. trajectory) of the
application material 570. For example, if the ultrasonic material delivery device 510 were grounded during application of theapplication material 570, the behavior of theapplication material 570 may be different if theimplantable device 180 had an electric charge while theconductive member 590 was grounded compared to theimplantable device 180 being grounded while theconductive member 590 had an electric charge. In the example with the chargedimplantable device 180 and groundedconductive member 590, theapplication material 570 may have a generally more direct trajectory toward theimplantable device 180 than in the example where theimplantable device 180 is grounded and theconductive member 590 has an electric charge. - In another example, if the ultrasonic material delivery device 510 were grounded during application of the
application material 570 and theconductive member 590 had an electric charge while theimplantable device 180 was grounded, the trajectory of theapplication material 570 may be more direct with respect to theimplantable device 180 if the quantity of electric charge of theconductive member 590 were larger than if the quantity of electric charge of theconductive member 590 were smaller. Which system components may have an electric charge or be grounded, the position (i.e. location and/or orientation) of the system components, as well as the quantity of electric charge of the charged system components may be generally selected based on a desiredapplication material 570 trajectory. -
FIG. 6 illustrates a further embodiment of amethod 600 for applying an application material to an implantable device, in accordance with the present invention. In the present embodiment, themethod 600 may be used in conjunction with components of thesystems FIGS. 1 , 3, and 5 and/or any other system for applying an application material to an implantable device described herein. For example, the ultrasonic material delivery apparatus may include anultrasonic generator 320 and/or amaterial delivery apparatus 330, which may be selectively electrically isolated from each other. - The
method 600 of this further embodiment may be functionally similar to that of themethods FIGS. 2 and 4 in most respects, wherein certain features will not be described in relation to this further embodiment wherein those method components may be performed in the manner as described above and are hereby incorporated into this alternative embodiment described below. - An implantable device may be positioned between an ultrasonic material delivery apparatus and a conductive member, as represented by
block 602. Positioning an implantable device between an ultrasonic material delivery apparatus and a conductive member may include orienting the implantable device between an ultrasonic material delivery apparatus and a conductive member. For example, a stent may be positioned such that it is about 30 mm from a nozzle of an ultrasonic material delivery apparatus and near the conductive member and/or may be oriented perpendicular to the application material being applied. - In some embodiments, before and/or during application of the application material to the implantable device, an electric charge may be applied to the ultrasonic material delivery apparatus, the implantable device, and/or the conductive member. In further embodiments, before and/or during application of the application material to the implantable device, no more than two of the ultrasonic material delivery apparatus, the implantable device, and conductive member may be grounded.
- Application material may then be applied to the implantable device, as represented by
block 604. -
FIG. 7 illustrates a block diagram of a still further embodiment of asystem 700 for applying anapplication material 770 to animplantable device 180, in accordance with the present invention. Thesystem 700 of this still further embodiment may be functionally similar to that of thesystems FIGS. 1 , 3, and 5 in many respects, wherein certain features will not be described in relation to this still further embodiment wherein those components may function in the manner as described above and are hereby incorporated into this alternative embodiment described below. - The
system 700 includes an ultrasonic material delivery apparatus 710 that may apply anapplication material 770 to animplantable device 180 and may include aconductive member 790. The ultrasonic material delivery apparatus 710, in the present embodiment, may include anultrasonic power generator 722, atransducer 724, ahousing 732, anozzle body 734, anozzle holder 736, anultrasonic transducer horn 738, apressure source 740, anapplication material reservoir 750, and/or an applicationmaterial delivery apparatus 760. - The
system 700, in the present embodiment, may include an ultrasonic generator. The ultrasonic generator may include anultrasonic power generator 722 and at least onetransducer 724. Theultrasonic power generator 722 may generate high frequency electrical energy. High frequency electrical energy may be generated in the range, for example, from about 20 kHz to about 120 kHz. The frequency may be determined based on the characteristics of thenozzle body 734 and/orultrasonic horn 738. - The
ultrasonic power generator 722 may be in electrical communication with at least onetransducer 724. The at least onetransducer 724 may convert the electrical energy generated by theultrasonic power generator 722 into mechanical (i.e. vibration) energy. Thetransducers 724 may include piezoelectric transducers to facilitate in atomizing theapplication material 770. - The
housing 732 may house thenozzle body 734. Thehousing 732 may be connected to thenozzle holder 736. Thenozzle holder 736 may be used to position the ultrasonic material delivery apparatus 710 with respect to theimplantable device 180 and/orconductive member 790. - In the present embodiment, the material delivery apparatus (not shown) may include both an application
material delivery apparatus 760 and anozzle body 734 andultrasonic horn 738. In other embodiments, other configurations may be used. For example, thenozzle body 734 andultrasonic horn 738 may be in fluid communication with theapplication material reservoir 750 and apressure source 740. - The
nozzle body 734 and/or theultrasonic horn 738, in the present embodiment, may be in fluid communication with apressure source 740. Thepressure source 740, in the present embodiment, may include an air pressure source. Thepressure source 740 may generate a pressurized fluid that may be shaped and/or directed by thenozzle body 734 and/or theultrasonic horn 738. Thepressure source 740, in the present embodiment, may generate a low-pressure air stream. In one embodiment,ultrasonic horn 738 may be hollow with the gas frompressure source 740 passing through it. - The application
material delivery apparatus 760 may be connected to anapplication material reservoir 750. Theapplication material reservoir 750 may include a pump, pressurized reservoir, gravity system, and/or other delivery mechanism to direct theapplication material 770 to the applicationmaterial delivery apparatus 760. The applicationmaterial delivery apparatus 760 may include a hypotube. The applicationmaterial delivery apparatus 760 may deliver theapplication material 770 to theultrasonic horn 738 to facilitate atomization of theapplication material 770. In some embodiments, the applicationmaterial delivery apparatus 760 may have an electric charge and/or be grounded. In further embodiments, the applicationmaterial delivery apparatus 760 may be selectively electrically isolated from theultrasonic power generator 722. - As in the previous embodiments, which system components may have an electric charge or be grounded as well as the quantity of electric charge of the charged system components may be generally selected based on a desired
application material 770 trajectory. -
FIG. 8 illustrates a still further embodiment of amethod 800 for applying an application material to an implantable device, in accordance with the present invention. Themethod 800 may utilize systems for applying a coating to an implantable device such as thesystems FIGS. 1 , 3, 5, and 7. Components of thesesystems material delivery apparatus 760, atransducer 724, anultrasonic power generator 722, and/or other system components), animplantable device 180, and/or aconductive member 590. - The
method 800 of this still further embodiment may be functionally similar to that of themethods FIGS. 2 , 4, and 6 in most respects, wherein certain features will not be described in relation to this still further embodiment wherein those method components may be performed in the manner as described above and are hereby incorporated into this alternative embodiment described below. - An electric charge may be applied to a component of a system for applying a coating to an implantable device, as represented by
block 802. The electric charge applied to a component of a system for applying a coating to an implantable device may be applied before and/or maintained during application of the application material. For example, an electric charge may be applied to an application material delivery apparatus during application of the application material. - The implantable device may be positioned relative to an ultrasonic material delivery apparatus, as represented by
block 804. The implantable device may be positioned between the ultrasonic material delivery apparatus and a conductive member, as represented byblock 806. Ultrasonic energy may be applied to an application material using an ultrasonic generator, as represented byblock 808. Application material may be applied to the implantable device, as represented byblock 810. -
FIG. 9 illustrates a block diagram of an even further embodiment of asystem 900 for applying anapplication material 970 to animplantable device 180, in accordance with the present invention. Thesystem 900 of this embodiment may be functionally similar to that ofsystems FIGS. 1 , 3, 5, and 7 in many respects. As such, certain features will not be described in relation to this embodiment wherein those components may function in the manner as described above and are hereby incorporated into this alternative embodiment described below. Like structures or components are give like reference numerals. - The
system 900 includes an ultrasonic material delivery apparatus 910 that may apply anapplication material 970 to animplantable device 180 and may include aconductive member 990. The ultrasonic material delivery apparatus 910 may include anultrasonic generator 320 and/or amaterial delivery apparatus 330. - The
conductive member 990 may include an electrically conductive material such as platinum, gold, silver, copper, stainless steel, and/or other electrically conductive materials. As shown inFIG. 9 , theconductive member 990 may have an electric charge (shown as positive) applied to it. The ultrasonic material delivery apparatus 910, theimplantable device 180, theconductive member 990, and/or a combination of the three may have an electric charge, may be grounded, and/or may have an electric charge applied during application of theapplication material 970. However, at least one of the ultrasonic material delivery apparatus 910, theimplantable device 180, and theconductive member 990, in the present embodiment, has an electric charge or has an applied electric charge during application of the application material (i.e., in one configuration no more than two of the ultrasonic material delivery apparatus 910, theimplantable device 180, and theconductive member 990 may be grounded during application of the application material). - Similar to the previous embodiments, in embodiments where the
application material 970,implantable device 180, and/or theconductive member 990 have an electric charge, theapplication material 970 may be generally attracted to or generally repelled from theimplantable device 180 and/or theconductive member 990. In some embodiments, the voltage potential difference between theapplication material 970 and theimplantable device 180 and/orconductive member 990 may be sufficiently large to facilitate atomization of theapplication material 970. - In the present embodiment, the
conductive member 990 may be positioned between the ultrasonic material delivery apparatus 910 and theimplantable device 180. In other embodiments, the ultrasonic material delivery apparatus 910, the conductive member, and/or theimplantable device 180 may be otherwise positioned. - The
conductive member 990 is illustrated inFIG. 9 as an annular ring. In other embodiments, theconductive member 990 may be tubular, cylindrical, spherical, rectangular, and/or otherwise shaped to perform the desired function of aiding to direct the flow of application material to the implantable device. - The
conductive member 990 may perform additional functions. For example, theconductive member 990 may include a focusing assembly that uses a deflecting fluid to focus the trajectory of theapplication material 970. Deflecting a fluid path using a focusing assembly may be accomplished as disclosed in U.S. Patent Application No. 61/015,137, filed Dec. 19, 2007, and entitled “METHODS FOR APPLYING AN APPLICATION MATERIAL TO AN IMPLANTABLE DEVICE”, which is incorporated herein by reference in its entirety. For example, theconductive member 990 may include an annular focusing jet to deflect the trajectory of theapplication material 970. - As in the previous embodiments, which system components may have an electric charge or be grounded as well as the magnitude of electric charge of the charged system components may be generally selected based on a desired
application material 970 trajectory. -
FIG. 10 illustrates a schematic representation of an embodiment of asystem 1000 for applying anapplication material 1070 to animplantable device 1080, in accordance with the present invention. Thesystem 1000 of this embodiment may be functionally similar to that ofsystems FIGS. 1 , 3, 5, 7, and 9 in many respects, wherein certain features will not be described in relation to this embodiment wherein those components may function in the manner as described above and are hereby incorporated into this alternative embodiment described below. Like structures or components are give like reference numerals. - The
system 1000 may include an ultrasonicmaterial delivery apparatus 1010 that may apply anapplication material 1070 to animplantable device 1080. The delivery or loading of theapplication material 1070 to theimplantable device 1080 can be varied through use of acontroller 1002, the ultrasonicmaterial delivery apparatus 1010, apositioning assembly 1012, and/or other components. For instance, thecontroller 1002 can be programmed with the structural configuration of theimplantable device 1080 and control delivery or loading theapplication material 1070 through controlling the operation of the ultrasonicmaterial delivery apparatus 1010, thepositioning assembly 1012, and/or other components. Other components may include a focusing assembly that may deflect or change a spray pattern of theapplication material 1070. In this manner, the invention reduces or eliminates webbing and bridging of application material across openings or gaps within the structure of the prosthesis and minimizes waste. - The
positioning assembly 1012 can include adriver assembly 1020 that creates relative movement between theimplantable device 1080 and the ultrasonicmaterial delivery apparatus 1010. Thepositioning assembly 1012 can also include arotation assembly 1013 that creates rotational movement of theimplantable device 1080 and/or aholder 1014 configured to support and/or rotate theimplantable device 1080. - As mentioned above, the
controller 1002 in communication with thedriver assembly 1020 can define a dispensing path of relative movement between the ultrasonicmaterial delivery apparatus 1010 and therotation assembly 1013. Thecontroller 1002 can also communicate with the ultrasonicmaterial delivery apparatus 1010 for selectively dispensingapplication material 1070 in a selected format along the dispensing path onto a selected portion of theimplantable device 1080 supported by theholder 1014. In one configuration, therotation assembly 1013 supporting theimplantable device 1080 is longitudinally moveable while the ultrasonicmaterial delivery apparatus 1010 remains stationary during dispensing ofapplication material 1070. However, in another aspect of the invention therotation assembly 1013 supporting theimplantable device 1080 may remain longitudinally stationary (although may still rotate) while the ultrasonicmaterial delivery apparatus 1010 moves along the dispensing path. Alternatively, both therotation assembly 1013 and ultrasonicmaterial delivery apparatus 1010 are longitudinally moveable. - In another configuration, the
system 1000 can include a detector or sensor to detect when the ultrasonicmaterial delivery apparatus 1010 is aligned with the selected portions of theimplantable device 1080. Such a detector or sensor can be an optical detector, e.g., linear array detector or infrared detector, ultrasound probe, temperature probe, camera, capacitance meter, electrometer, hall-effect probe, and the like, or any other sensor or detector known in the art for detection. - In a further configuration, the
system 1000 can include a focusing assembly to aid delivery orloading application material 1070 through varying or changing the spray pattern of theapplication material 1070. The focusing assembly may include at least one focusing jet, an annular jet, and/or other focusing assembly components. - With continued reference to
FIG. 10 , thepositioning assembly 1012 can further include alongitudinal driver 1018. Therotation assembly 1013 can likewise further include arotating driver 1016. Theholder 1014 may be rotated through therotation driver 1016, which can include a motor. For instance, the rotatingdriver 1016 can be activated to produce a constant angular velocity on theimplantable device 1080 during application material delivery. Similarly, thelongitudinal driver 1018 can control advancement of theimplantable device 1080 longitudinally past the ultrasonicmaterial delivery apparatus 1010. Again, thelongitudinal driver 1018 can include a motor. - Through the
system 1000,application material 1070 can be loaded or delivered to animplantable device 1080 in a controlled manner. Thesystem 1000 enables and facilitates relative movement between thematerial application apparatus 1010 and theimplantable device 1080 to define a dispensing path along which theapplication material 1070 can be selectively dispensed. Thepositioning assembly 1012 and/orrotation assembly 1013 may aid the delivery or loading of theapplication material 1070 through varying or changing the spray pattern of theapplication material 1070. Hence, theapplication material 1070 is selectively dispensed from the ultrasonicmaterial delivery apparatus 1010 to a predetermined portion of theimplantable device 1080 along the dispensing path. - The dispensing path can include, for example, a sequential series of linear parallel passes that traverse back and forth along one axis of the
implantable device 1080. The relative motion can be continued in a linear manner between forward and backward or right to left and left to right or upward and downward, depending on the frame of reference. A traversal or a pass can be completed when the relative motion reverses direction. That is, relative motion continues past the implantable device, and then decelerates, stops, reverses direction, and/or accelerates to a constant velocity. After each pass, thesystem 1000 may adjust the position of the ultrasonicmaterial delivery apparatus 1010 and/orimplantable device 1080 relative to the ultrasonicmaterial delivery apparatus 1010 can be changed or incremented to limit the possibility of application overlap, although a certain degree of overlap may be permitted. - Alternatively, the dispensing path created by the relative motion of the ultrasonic
material delivery apparatus 1010 and theimplantable device 1080 can include a single continuous helix that wraps continuously around the implantable device tubular body and along the length of theimplantable device 1080. Alternatively, the dispensing path can include a non-continuous helix. - The invention is susceptible to various modifications and alternative means, and specific examples thereof have been shown by way of example in the drawings and are herein described in detail. It should be understood, however, that the invention is not to be limited to the particular devices or methods disclosed, but to the contrary, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the claims.
Claims (31)
1. A method for applying a coating to an implantable device, comprising:
positioning an implantable device relative to an ultrasonic material delivery apparatus, the ultrasonic material delivery apparatus including an ultrasonic generator, at least one of the ultrasonic material delivery apparatus and the implantable device having a positive or negative electric charge; and
applying an application material to the implantable device using the ultrasonic material delivery apparatus.
2. The method of claim 1 , wherein the ultrasonic material delivery apparatus further comprises a material delivery device and at least one of the material delivery device and the implantable device having a positive or negative electric charge.
3. The method of claim 2 , wherein the material delivery device being selectively electrically isolated from the ultrasonic generator.
4. The method of claim 2 , wherein the material delivery apparatus combines ultrasonic atomization with a flowing gas stream.
5. The method of claim 1 , wherein the ultrasonic material delivery apparatus has a positive or negative electric charge and the positive or negative electric charge is of sufficient strength to facilitate atomization of the application material.
6. The method of claim 1 , further comprising positioning the implantable device between the ultrasonic material delivery apparatus and a conductive member.
7. The method of claim 6 , wherein the conductive member either has a positive or a negative charge or is grounded.
8. The method of claim 1 , further comprising positioning a conductive member between the implantable device and the ultrasonic material delivery apparatus.
9. The method of claim 8 , wherein the conductive member either has a positive or a negative charge or is grounded.
10. The method of claim 1 , wherein the implantable device, the ultrasonic material delivery apparatus, or the conductive member have a difference in electrical potential of less than or equal to about 100 kV in either a positive or negative polarity.
11. The method of claim 1 , wherein both the implantable device and the ultrasonic material delivery apparatus have either a positive or a negative charge.
12. The method of claim 1 , wherein applying the application material to the implantable device using the ultrasonic material delivery apparatus further comprises applying ultrasonic energy to the application material using the ultrasonic generator.
13. The method of claim 12 , wherein the applied ultrasonic energy is sufficient to facilitate atomization of the application material.
14. The method of claim 1 , wherein the application material includes a radiopaque material.
15. The method of claim 1 , wherein the application material includes at least one bioactive agent that is an anti-proliferative, anti-inflammatory, antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic, antibiotic, antiallergic or antioxidant drug.
16. The method of claim 1 , wherein the application material includes a durable or biodegradable polymer.
17. The method of claim 1 , wherein the application material includes a solvent.
18. The method of claim 1 , wherein the implantable device is a closure element.
19. The method of claim 1 , wherein the implantable device is a stent.
20. The method of claim 2 , further comprising at least one of the material delivery device and the implantable device being grounded.
21. A method for applying a coating to an implantable device, the method comprising:
positioning an implantable device between a conductive member and an ultrasonic material delivery apparatus, the ultrasonic material delivery apparatus including an ultrasonic generator, and the conductive member either having a positive or a negative charge; and
applying an application material to the implantable device using the ultrasonic material delivery apparatus.
22. The method of claim 21 , further comprising at least one of the ultrasonic material delivery apparatus and the implantable device being grounded.
23. The method of claim 21 , wherein the application material includes a radiopaque material.
24. The method of claim 21 , wherein the application material includes at least one bioactive agent that is an anti-proliferative, anti-inflammatory, antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic, antibiotic, antiallergic or antioxidant drug.
25. A method for applying a coating to a stent, the method comprising:
positioning a stent between an ultrasonic material delivery apparatus and a grounded conductive member, the ultrasonic material delivery apparatus including an ultrasonic generator, at least one of the ultrasonic material delivery apparatus and the stent having a positive or negative electric charge;
applying ultrasonic energy to an application material using the ultrasonic generator; and
applying the application material to the stent using the ultrasonic material delivery apparatus.
26. The method of claim 25 , wherein the applied ultrasonic energy is sufficient to facilitate atomization of the application material.
27. The method of claim 25 , wherein the stent has a positive or negative electric charge and the positive or negative electric charge is of sufficient strength to facilitate atomization of the application material.
28. A method for applying a coating to an implantable device, the method comprising:
positioning a conductive member between an implantable device and an ultrasonic material delivery apparatus, the ultrasonic material delivery apparatus including an ultrasonic generator, and the conductive member either having a positive or a negative charge; and
applying an application material to the implantable device using the ultrasonic material delivery apparatus.
29. The method of claim 28 , further comprising at least one of the ultrasonic material delivery apparatus and the implantable device being grounded.
30. The method of claim 28 , wherein the application material includes a radiopaque material.
31. The method of claim 28 , wherein the application material includes at least one bioactive agent that is an anti-proliferative, anti-inflammatory, antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic, antibiotic, antiallergic or antioxidant drug.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/331,290 US8361538B2 (en) | 2007-12-19 | 2008-12-09 | Methods for applying an application material to an implantable device |
PCT/US2008/086259 WO2009085618A2 (en) | 2007-12-19 | 2008-12-10 | Methods for applying an application material to an implantable device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1512607P | 2007-12-19 | 2007-12-19 | |
US12/331,290 US8361538B2 (en) | 2007-12-19 | 2008-12-09 | Methods for applying an application material to an implantable device |
Publications (2)
Publication Number | Publication Date |
---|---|
US20090181159A1 true US20090181159A1 (en) | 2009-07-16 |
US8361538B2 US8361538B2 (en) | 2013-01-29 |
Family
ID=40638172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/331,290 Expired - Fee Related US8361538B2 (en) | 2007-12-19 | 2008-12-09 | Methods for applying an application material to an implantable device |
Country Status (2)
Country | Link |
---|---|
US (1) | US8361538B2 (en) |
WO (1) | WO2009085618A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090181160A1 (en) * | 2007-12-19 | 2009-07-16 | Abbott Laboratories | Methods for applying an application material to an implantable device |
US8361538B2 (en) | 2007-12-19 | 2013-01-29 | Abbott Laboratories | Methods for applying an application material to an implantable device |
EP3275559A1 (en) * | 2016-07-27 | 2018-01-31 | Exel Industries | Coating system with an ultrasonic spray head and electrostatic field |
JP7455834B2 (en) | 2018-11-29 | 2024-03-26 | エシコン・インコーポレイテッド | Operating room coating applicator and method thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2814618B1 (en) * | 2012-02-16 | 2017-04-05 | Sahajanand Technologies Private Limited | Drug coating apparatus |
GB2537171B (en) * | 2015-04-10 | 2020-09-23 | Biomet Uk Healthcare Ltd | A method and apparatus for applying a bone attachment coating |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4541564A (en) * | 1983-01-05 | 1985-09-17 | Sono-Tek Corporation | Ultrasonic liquid atomizer, particularly for high volume flow rates |
US4642581A (en) * | 1985-06-21 | 1987-02-10 | Sono-Tek Corporation | Ultrasonic transducer drive circuit |
US4978067A (en) * | 1989-12-22 | 1990-12-18 | Sono-Tek Corporation | Unitary axial flow tube ultrasonic atomizer with enhanced sealing |
US5219120A (en) * | 1991-07-24 | 1993-06-15 | Sono-Tek Corporation | Apparatus and method for applying a stream of atomized fluid |
US6696121B2 (en) * | 1997-05-14 | 2004-02-24 | Abbott Laboratories Vascular Enterprises Limited | Balloon for a dilation catheter and method for manufacturing a balloon |
US20040062875A1 (en) * | 2002-09-27 | 2004-04-01 | Surmodics, Inc. | Advanced coating apparatus and method |
US6861088B2 (en) * | 2002-03-28 | 2005-03-01 | Boston Scientific Scimed, Inc. | Method for spray-coating a medical device having a tubular wall such as a stent |
US20060198940A1 (en) * | 2005-03-04 | 2006-09-07 | Mcmorrow David | Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance |
US20070128343A1 (en) * | 2005-11-15 | 2007-06-07 | Chappa Ralph A | Apparatus And Methods for Applying Coatings |
US20070254091A1 (en) * | 2006-04-28 | 2007-11-01 | Boston Scientific Scimed, Inc. | System and method for electrostatic-assisted spray coating of a medical device |
US7504125B1 (en) * | 2001-04-27 | 2009-03-17 | Advanced Cardiovascular Systems, Inc. | System and method for coating implantable devices |
US7951428B2 (en) * | 2006-01-31 | 2011-05-31 | Regents Of The University Of Minnesota | Electrospray coating of objects |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR732895A (en) | 1932-10-18 | 1932-09-25 | Consortium Elektrochem Ind | Articles spun in polyvinyl alcohol |
DE1152920B (en) | 1952-09-18 | 1963-08-14 | Licentia Gmbh | Process for covering objects in an electric field |
US3882816A (en) | 1972-09-22 | 1975-05-13 | Western Electric Co | Apparatus for forming layers of fusible metal on articles |
GB1455862A (en) | 1973-11-06 | 1976-11-17 | Nat Res Dev | Spraying atomised particles |
US3995075A (en) | 1974-04-18 | 1976-11-30 | Continental Can Company, Inc. | Inside stripe by intermittent exterior spray guns |
US4323524A (en) | 1977-03-11 | 1982-04-06 | Imperial Chemical Industries Limited | Production of fibres |
DE2935097A1 (en) | 1978-09-07 | 1980-03-20 | Kuraray Co | AETHYLENE / VINYL ALCOHOL COPOLYMER MEMBRANE |
US4560374A (en) | 1983-10-17 | 1985-12-24 | Hammerslag Julius G | Method for repairing stenotic vessels |
JPS61276561A (en) | 1985-05-31 | 1986-12-06 | 株式会社クラレ | Blood treatment apparatus |
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US4865879A (en) | 1988-03-31 | 1989-09-12 | Gordon Finlay | Method for restoring and reinforcing wooden structural component |
US5328471A (en) | 1990-02-26 | 1994-07-12 | Endoluminal Therapeutics, Inc. | Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens |
US4977901A (en) | 1988-11-23 | 1990-12-18 | Minnesota Mining And Manufacturing Company | Article having non-crosslinked crystallized polymer coatings |
US5971954A (en) | 1990-01-10 | 1999-10-26 | Rochester Medical Corporation | Method of making catheter |
JP2730702B2 (en) | 1990-02-26 | 1998-03-25 | エンドルミナル セラピューティックス,インコーポレイテッド | Device for treating lesions in hollow vessels and other tissue lumens |
US6060451A (en) | 1990-06-15 | 2000-05-09 | The National Research Council Of Canada | Thrombin inhibitors based on the amino acid sequence of hirudin |
CA2081896A1 (en) | 1990-06-15 | 1991-12-16 | James E. Shapland | Drug delivery apparatus and method |
US5112457A (en) | 1990-07-23 | 1992-05-12 | Case Western Reserve University | Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants |
US5455040A (en) | 1990-07-26 | 1995-10-03 | Case Western Reserve University | Anticoagulant plasma polymer-modified substrate |
US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
EG20321A (en) | 1993-07-21 | 1998-10-31 | Otsuka Pharma Co Ltd | Medical material and process for producing the same |
US5723004A (en) | 1993-10-21 | 1998-03-03 | Corvita Corporation | Expandable supportive endoluminal grafts |
US5670558A (en) | 1994-07-07 | 1997-09-23 | Terumo Kabushiki Kaisha | Medical instruments that exhibit surface lubricity when wetted |
US5578073A (en) | 1994-09-16 | 1996-11-26 | Ramot Of Tel Aviv University | Thromboresistant surface treatment for biomaterials |
US5558900A (en) | 1994-09-22 | 1996-09-24 | Fan; You-Ling | One-step thromboresistant, lubricious coating |
US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5569198A (en) | 1995-01-23 | 1996-10-29 | Cortrak Medical Inc. | Microporous catheter |
US6017577A (en) | 1995-02-01 | 2000-01-25 | Schneider (Usa) Inc. | Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices |
US5919570A (en) | 1995-02-01 | 1999-07-06 | Schneider Inc. | Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices |
US5605696A (en) | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US6120536A (en) | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US5820917A (en) | 1995-06-07 | 1998-10-13 | Medtronic, Inc. | Blood-contacting medical device and method |
AU716005B2 (en) | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
US6010530A (en) | 1995-06-07 | 2000-01-04 | Boston Scientific Technology, Inc. | Self-expanding endoluminal prosthesis |
US5609629A (en) | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US5667767A (en) | 1995-07-27 | 1997-09-16 | Micro Therapeutics, Inc. | Compositions for use in embolizing blood vessels |
GB9522332D0 (en) | 1995-11-01 | 1996-01-03 | Biocompatibles Ltd | Braided stent |
JP4193917B2 (en) | 1995-12-18 | 2008-12-10 | アンジオデバイス インターナショナル ゲーエムベーハー | Crosslinked polymer composition and method of use thereof |
ATE302599T1 (en) | 1996-05-24 | 2005-09-15 | Angiotech Pharm Inc | PREPARATIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF DISEASES OF THE BODY PASSAGES |
US5830178A (en) | 1996-10-11 | 1998-11-03 | Micro Therapeutics, Inc. | Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide |
WO1998007523A1 (en) | 1996-08-23 | 1998-02-26 | Pursley Matt D | Apparatus and method for nonextrusion manufacturing of catheters |
US5980972A (en) | 1996-12-20 | 1999-11-09 | Schneider (Usa) Inc | Method of applying drug-release coatings |
US5997517A (en) | 1997-01-27 | 1999-12-07 | Sts Biopolymers, Inc. | Bonding layers for medical device surface coatings |
US5879697A (en) | 1997-04-30 | 1999-03-09 | Schneider Usa Inc | Drug-releasing coatings for medical devices |
US6056993A (en) | 1997-05-30 | 2000-05-02 | Schneider (Usa) Inc. | Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel |
US5891507A (en) | 1997-07-28 | 1999-04-06 | Iowa-India Investments Company Limited | Process for coating a surface of a metallic stent |
US5980928A (en) | 1997-07-29 | 1999-11-09 | Terry; Paul B. | Implant for preventing conjunctivitis in cattle |
US6121027A (en) | 1997-08-15 | 2000-09-19 | Surmodics, Inc. | Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups |
US6015541A (en) | 1997-11-03 | 2000-01-18 | Micro Therapeutics, Inc. | Radioactive embolizing compositions |
US6110188A (en) | 1998-03-09 | 2000-08-29 | Corvascular, Inc. | Anastomosis method |
US6113629A (en) | 1998-05-01 | 2000-09-05 | Micrus Corporation | Hydrogel for the therapeutic treatment of aneurysms |
CA2332314A1 (en) | 1998-06-11 | 1999-12-16 | Cerus Corporation | Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells |
US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
AU4645299A (en) | 1998-07-08 | 2000-02-01 | Advanced Biocompatible Coatings Inc. | Biocompatible metallic stents with hydroxy methacrylate coating |
EP1119379A1 (en) | 1998-09-02 | 2001-08-01 | Boston Scientific Limited | Drug delivery device for stent |
US6407009B1 (en) | 1998-11-12 | 2002-06-18 | Advanced Micro Devices, Inc. | Methods of manufacture of uniform spin-on films |
US6358567B2 (en) | 1998-12-23 | 2002-03-19 | The Regents Of The University Of California | Colloidal spray method for low cost thin coating deposition |
US6364903B2 (en) | 1999-03-19 | 2002-04-02 | Meadox Medicals, Inc. | Polymer coated stent |
US6368658B1 (en) | 1999-04-19 | 2002-04-09 | Scimed Life Systems, Inc. | Coating medical devices using air suspension |
EP1175236A1 (en) | 1999-04-23 | 2002-01-30 | Agion Technologies, L.L.C. | Stent having antimicrobial agent |
US6156373A (en) | 1999-05-03 | 2000-12-05 | Scimed Life Systems, Inc. | Medical device coating methods and devices |
US6426145B1 (en) | 1999-05-20 | 2002-07-30 | Scimed Life Systems, Inc. | Radiopaque compositions for visualization of medical devices |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US6503954B1 (en) | 2000-03-31 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing actinomycin D and a method of forming the same |
US6713119B2 (en) | 1999-09-03 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for a prosthesis and a method of forming the same |
US6818247B1 (en) | 2000-03-31 | 2004-11-16 | Advanced Cardiovascular Systems, Inc. | Ethylene vinyl alcohol-dimethyl acetamide composition and a method of coating a stent |
US6395326B1 (en) | 2000-05-31 | 2002-05-28 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for depositing a coating onto a surface of a prosthesis |
US6555157B1 (en) | 2000-07-25 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Method for coating an implantable device and system for performing the method |
US6534112B1 (en) | 2000-08-01 | 2003-03-18 | Ams Research Corporation | Semi-automatic coating system methods for coating medical devices |
DE102004001095A1 (en) | 2004-01-05 | 2005-07-28 | Blue Membranes Gmbh | RF sputtering |
US8211489B2 (en) | 2007-12-19 | 2012-07-03 | Abbott Cardiovascular Systems, Inc. | Methods for applying an application material to an implantable device |
US8361538B2 (en) | 2007-12-19 | 2013-01-29 | Abbott Laboratories | Methods for applying an application material to an implantable device |
-
2008
- 2008-12-09 US US12/331,290 patent/US8361538B2/en not_active Expired - Fee Related
- 2008-12-10 WO PCT/US2008/086259 patent/WO2009085618A2/en active Application Filing
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4541564A (en) * | 1983-01-05 | 1985-09-17 | Sono-Tek Corporation | Ultrasonic liquid atomizer, particularly for high volume flow rates |
US4642581A (en) * | 1985-06-21 | 1987-02-10 | Sono-Tek Corporation | Ultrasonic transducer drive circuit |
US4978067A (en) * | 1989-12-22 | 1990-12-18 | Sono-Tek Corporation | Unitary axial flow tube ultrasonic atomizer with enhanced sealing |
US5219120A (en) * | 1991-07-24 | 1993-06-15 | Sono-Tek Corporation | Apparatus and method for applying a stream of atomized fluid |
US6696121B2 (en) * | 1997-05-14 | 2004-02-24 | Abbott Laboratories Vascular Enterprises Limited | Balloon for a dilation catheter and method for manufacturing a balloon |
US7504125B1 (en) * | 2001-04-27 | 2009-03-17 | Advanced Cardiovascular Systems, Inc. | System and method for coating implantable devices |
US8007858B2 (en) * | 2001-04-27 | 2011-08-30 | Advanced Cardiovascular Systems, Inc. | System and method for coating implantable devices |
US20090136556A1 (en) * | 2001-04-27 | 2009-05-28 | Advanced Cardiovascular Systems, Inc. | System And Method For Coating Implantable Devices |
US6861088B2 (en) * | 2002-03-28 | 2005-03-01 | Boston Scientific Scimed, Inc. | Method for spray-coating a medical device having a tubular wall such as a stent |
US20040062875A1 (en) * | 2002-09-27 | 2004-04-01 | Surmodics, Inc. | Advanced coating apparatus and method |
US20060198940A1 (en) * | 2005-03-04 | 2006-09-07 | Mcmorrow David | Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance |
US20070128343A1 (en) * | 2005-11-15 | 2007-06-07 | Chappa Ralph A | Apparatus And Methods for Applying Coatings |
US7951428B2 (en) * | 2006-01-31 | 2011-05-31 | Regents Of The University Of Minnesota | Electrospray coating of objects |
US20070254091A1 (en) * | 2006-04-28 | 2007-11-01 | Boston Scientific Scimed, Inc. | System and method for electrostatic-assisted spray coating of a medical device |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090181160A1 (en) * | 2007-12-19 | 2009-07-16 | Abbott Laboratories | Methods for applying an application material to an implantable device |
US8211489B2 (en) | 2007-12-19 | 2012-07-03 | Abbott Cardiovascular Systems, Inc. | Methods for applying an application material to an implantable device |
US8361538B2 (en) | 2007-12-19 | 2013-01-29 | Abbott Laboratories | Methods for applying an application material to an implantable device |
EP3275559A1 (en) * | 2016-07-27 | 2018-01-31 | Exel Industries | Coating system with an ultrasonic spray head and electrostatic field |
KR20180012704A (en) * | 2016-07-27 | 2018-02-06 | 엑셀 인더스트리스 | Coating system with an ultrasonic head |
US10307773B2 (en) | 2016-07-27 | 2019-06-04 | Exel Industries | Coating system with an ultrasonic head |
KR102428094B1 (en) * | 2016-07-27 | 2022-08-02 | 엑셀 인더스트리스 | Coating system with an ultrasonic head |
JP7455834B2 (en) | 2018-11-29 | 2024-03-26 | エシコン・インコーポレイテッド | Operating room coating applicator and method thereof |
Also Published As
Publication number | Publication date |
---|---|
US8361538B2 (en) | 2013-01-29 |
WO2009085618A2 (en) | 2009-07-09 |
WO2009085618A3 (en) | 2009-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8632841B2 (en) | Systems and methods for rotating and coating an implantable device | |
US8361538B2 (en) | Methods for applying an application material to an implantable device | |
US8097292B2 (en) | Methods for electrostatic coating of an abluminal stent surface | |
US6572644B1 (en) | Stent mounting device and a method of using the same to coat a stent | |
US6565659B1 (en) | Stent mounting assembly and a method of using the same to coat a stent | |
US8007858B2 (en) | System and method for coating implantable devices | |
US8312838B2 (en) | Coating abluminal surfaces of stents and other implantable medical devices | |
US7507433B2 (en) | Method of coating a medical device using an electrowetting process | |
US8192785B2 (en) | Apparatus and method for coating implantable devices | |
US20060149365A1 (en) | Stent with eccentric coating | |
US20050192662A1 (en) | Stent with differently coated inside and outside surfaces | |
US20050238829A1 (en) | Differentially coated medical devices, system for differentially coating medical devices, and coating method | |
US20140072695A1 (en) | Direct fluid coating of drug eluting balloon | |
JP2008523901A (en) | Antiluminal multi-layer coating construct for drug delivery stent | |
EP1848371A1 (en) | Method of incorporating a drug-eluting external body in a medical appliance and a self-expanding stent including a drug-eluting external body | |
US7691431B2 (en) | System and method for spray coating multiple medical devices using a rotary atomizer | |
US20100126414A1 (en) | Mounting Assembly For A Stent And A Method Of Using The Same To Coat A Stent | |
US7390524B1 (en) | Method for electrostatic spraying of an abluminal stent surface | |
US8211489B2 (en) | Methods for applying an application material to an implantable device | |
US7481835B1 (en) | Encapsulated covered stent | |
WO2006044307A2 (en) | A magnetic levitation system for coating a device, a method of using the system, and device made by the system | |
KR101161151B1 (en) | Coating method for stents or biomedical implants by electrospray |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ABBOTT LABORATORIES, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PACETTI, STEPHEN;REEL/FRAME:021953/0141 Effective date: 20081119 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20170129 |